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ABSTRACT
Hormonal and nutritional stimuli coordinately regulate the glucose and lipid
metabolism in the liver. Dysregulated hormonal balance and nutrient metabolism not only
disrupt the energy homeostasis, but also predispose individuals to the development of
obesity and its related metabolic diseases. Research presented in this dissertation
investigated the effects of a nutritional factor, vitamin A (VA), and a potential component
of insulin signaling cascade, atypical protein kinase C (aPKC), on the glucose and lipid
metabolic genes transcription in primary hepatocytes from Zucker lean (ZL) and fatty
(ZF) rats.
To examine VA effects, we put ZL and ZF rats with different VA statuses on various
feeding conditions. After the isolation of their primary hepatocytes, we analyzed the
expressions of hepatic model genes in response to the treatments of insulin and retinoic
acid (RA). We report that the insulin- and RA-regulated glucokinase (Gck), sterol
regulatory

element-binding

protein-1c

(Srebp-1c)

and

cytosolic

form

of

phosphoenolpyruvate carboxykinase (Pck1) expressions are impaired in hepatocytes of
ZF rats fed chow or a VA sufficient (VAS) diet ad libitum. The impairment is partially
corrected when ZF rats are fed a VA deficient (VAD) diet ad libitum or pair-fed a VAS
diet to the intake of their VAD counterparts in non-fasting conditions. Interestingly, in
the pair-fed ZL and ZF rats, transient overeating on the last day of pair-feeding regimen
changes the expression levels of some VA catabolic genes, and impairs the insulin- and
RA-regulated gene expression in hepatocytes.
To investigate the roles of aPKC, PKCζ(zeta) and PKCι/λ(iota/lambda), they were
overexpressed in primary hepatocytes from ZL rats using recombinant adenoviruses.
aPKC overexpression in primary hepatocytes significantly attenuated the insulinregulated expressions of Gck, Srebp-1c and Pck1. Additionally, aPKC overexpression
increased their basal transcript levels. The impairment is associated with reduced protein
level of insulin receptor substrate 1, and the phosphorylation of protein kinase B in
response to insulin treatment.
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Taken together, the data demonstrate that feeding state, VA status, and aPKC
expression regulate the hepatic glucose and lipid metabolism at the gene expression level,
and provide interesting insights into the development of metabolic diseases.
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CHAPTER I. LITERATURE REVIEW ON INSULIN
SIGNALING PATHWAY, VITAMIN A AND ITS ROLES IN
THE REGULATION OF MACRONUTRIENT
METABOLISM.
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1. Metabolic diseases and metabolic syndromes
The prevalence of overweight and obesity has become a public health concern around
the world [1]. According to the World Health Organization’s 2010 report, 35% of adults
aged 20 years and older worldwide in 2008 were clinically overweight (body mass index,
BMI ≥ 25 kg/m2). More than half a billion adults in the same category were obese (BMI
≥ 30 kg/m2) [2]. Moreover, 2.8 million deaths are linked to raised BMI each year [2].
Overweight and obesity are associated with increased risks of developing an assortment
of metabolic diseases, which mainly include hypertension, type 2 diabetes mellitus, nonalcoholic fatty liver disease, coronary heart diseases and stroke [1,3]. The implications of
all those health conditions have brought gloomy biomedical and socioeconomic
consequences to the well-being of the global population [3].
In clinical settings, metabolic risk factors for the development of coronary heart
disease, type 2 diabetes mellitus and hypertension are collectively termed “metabolic
syndromes” [4]. This concept was established as “Syndrome X” by Reaven in 1988,
which mainly encompassed impaired glucose tolerance, hyperinsulinemia, and
dyslipidemia [5]. Over the past 25 years, the definition of metabolic syndrome has been
actively revised to reflect the latest epidemiologic and clinical data on the prevalence of
major metabolic diseases [6]. In 2005, the International Diabetes Federation introduced a
consensus diagnostic definition for metabolic syndromes. This definition stipulates
obesity (BMI ≥ 30 kg/m2) as a prerequisite factor, and the coexistence of two of the
following criteria: (1) triglyceride (TG) level ≥ 150 mg/dL; (2) high density lipoprotein
(HDL) level ≤ 40 mg/dL in men or ≤ 50 mg/dL in women; (3) systolic blood pressure ≥
130 mm Hg or diastolic blood pressure ≥ 85 mm Hg; (4) fasting blood glucose ≥ 100
mg/dL; (5) previous diagnosis or treatment of the abovementioned conditions [6].
Epidemiological studies demonstrate that metabolic syndromes are important
prognostic indicators for metabolic diseases [6]. An analysis of the National Health and
Nutrition Examination Survey (NHANES) II data shows that metabolic syndromes
strongly predict the mortality from coronary heart diseases in US adults [7]. Similar result
is confirmed in the Scandinavian Simvastatin Survival Study and the Air Force/Texas
Coronary Atherosclerosis Prevention Study [8]. Additionally, observations from the
Framingham Offspring Study show that metabolic syndromes are associated with
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significantly increased risks of developing type 2 diabetes [9]. Even though the
relationships among the risk factors that define metabolic syndromes have not been fully
unraveled, it appears that insulin resistance is a common link of the metabolic syndromes,
and plays a central role in the development of metabolic diseases [6].

2. Insulin signaling, insulin resistance and atypical protein kinase C
2.1 Insulin signaling: IRS/PI3K/AKT and IRS/PI3K/aPKC pathways
Insulin, which is secreted from pancreatic β-cells in response to physiological stimuli,
is an important peptide hormone in anabolism [10]. Upon secretion, it binds to the insulin
receptor on cell membranes and exerts its actions through a signal transduction cascade
mainly composed of kinases and phosphatases. The binding causes conformation changes
of the insulin receptor and transphosphorylation of the β-subunit tyrosine kinase [11,12],
which initiates the signal transduction cascade [13].
The insulin signal is transduced by multiple components in a complex network
comprised of multiple kinases and phosphatases [14,15]. Transphosphorylated insulin
receptor β subunit with open catalytic site is able to interact and phosphorylate an
assortment of substrate proteins on tyrosine residues [10]. These substrate proteins
include insulin receptor substrate 1~6 (IRS1~6), Src homology 2 domain-containing
transforming protein (SHC), Casitas B-lineage lymphoma protein (CBL), Grb2associated binder 1/2 (GAB1/2) and dedicator of cytokinesis protein 1/2 (DOCK1/2),
which mediate distinct physiological functions in vivo [10,15]. Transgenic animal studies
show that the majority of insulin responses are mediated by IRS1 and IRS2 [10].
Tyrosine phosphorylation of IRS1/2 leads to the association and activation of the
phosphatidylinositol 3-kinase (PI3K) [10,15]. PI3K catalyzes the conversion of
phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-triphosphate
(PIP3) [10,15]. The latter is a lipid messenger that anchors the downstream effector
proteins, e.g. phosphoinositide dependent protein kinase-1 (PDK1), protein kinase B
(PKB, also known as AKT) and atypical protein kinase C (aPKC), to the cell membrane
[10,15].
The interaction of PDK1 and AKT leads to the phosphorylation and activation of
AKT, which is a critical node in the signaling cascade to regulate multiple downstream
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physiological functions [10,15]. AKT is a member of the serine/threonine kinase family,
whose activation is postulated to be a multistep process [16]: (1) the insulin-independent
phosphorylation of Thr450 confers access to activation and translocation; (2) the PIP3
dependent translocation ensures the association of AKT with other kinases; (3) the
insulin-dependent phosphorylation of Thr308 and Ser473 confers maximal activity.
Recent data suggest that the phosphorylation of AKT at Thr308 is mediated by PDK1,
and the phosphorylation of AKT at Ser473 is dependent upon mammalian target of
rapamycin complex 2 (mTORC2) in Drosophila and human cells [17-19].
The activation of AKT regulates many downstream targets to control glucose and
lipid metabolism, protein synthesis, cell survival and proliferation, apoptosis and
neurophysiological functions [20]. For example in the regulation of glucose uptake into
muscle cells and adipocytes, AKT promotes the translocation of glucose transporter type
4 (GLUT4) containing vesicles to the cell membrane [21]. In the hepatocytes and muscle
cells, AKT activation leads to the phosphorylation and inactivation of glycogen synthase
kinase 3β (GSK3β), which in turn increases glycogen synthase (GS) activity and
glycogen synthesis [22]. In response to insulin and nutrient (e.g. amino acids) stimuli, the
activation of AKT participates in the upregulation of protein synthesis through mTORC1
[23]. Most importantly, the activation of AKT within a cell leads to the differential
regulation of metabolic genes expression, e.g. the induction of glucokinase (GCK, gene
Gck) to promote glycolysis, the induction of sterol-regulatory element binding protein 1c
(SREBP-1c, gene Srebp-1c) to promote lipogenesis and the suppression of
phosphoenolpyruvate carboxykinase to suppress gluconeogenesis (PEPCK, gene Pck1)
[24]. Given the important functions of AKT in vivo, the deregulation of AKT and its
downstream pathways is associated with cancer and metabolic diseases [20].
The transduction of insulin signaling system can also be mediated by aPKC. The
binding of aPKC to PIP3 prompts the conformational change in the kinase structure,
which provides access to the autophosphorylation and activation of the kinase [25]. aPKC
belongs to the protein kinase C family, and has two members: PKCζ and PKCι/λ [25]. It
is mainly localized to the cell membrane [26], and mediates a variety of physiological
events, including cell polarity establishment, cell motility, immune response and
signaling transduction [25]. So far, the majority of the aPKC targets remain uncovered.

!

4

However, recent studies with transgenic mice demonstrate the role of IRS/PI3K/aPKC
pathway in the regulation of metabolism. In both muscle cells and adipocytes, PI3K
dependent activation of aPKC is required for the GLUT4 translocation and glucose
uptake [27-29]. In hepatocytes, aPKC activation promotes the activity and expression of
SREBP-1c and the attendant expression of fatty acid synthase (FAS) and acetyl-CoA
carboxylase (ACC) [30-34]. aPKC activation also promotes transcription of proinflammatory cytokines by activating nuclear factor-kappaB (NF-κB) [34]. Additionally,
the activation of PKCι was elevated at the basal level and after insulin treatment in the
hepatocytes isolated from type 2 diabetic patients [35]. Treatment of these hepatocytes
with PKCι inhibitors lowered the levels of lipogenic, proinflammatory and gluconeogenic
enzymes [35,36]. These data collectively suggest that aPKCs are important players in the
pathogenesis of obesity and type 2 diabetes.
2.2 Insulin resistance
The activation of the insulin signaling pathway results in changes in the activities and
(or) the expression levels of enzymes in nutrient metabolism. These subsequently alter
the metabolic state of the tissues and organs in the body. For example, insulin promotes
glycolysis, glycogenesis, and lipogenesis, and at the same time, suppresses
gluconeogenesis in the liver [15]. However, in individuals with metabolic abnormalities
such as overweight and obesity, a certain dose of insulin only produces subnormal
physiological responses. This observation is regarded as insulin resistance, which occurs
concurrently with profound alterations in the glucose and lipid metabolism [10,37,38].
Even though the molecular mechanisms leading to insulin resistance has not been fully
understood, it is postulated that systemic inflammation, dysregulated lipid metabolism
and gastrointestinal dysbiosis, triggered by overnutrition, interplay with each other and
result in the impairment of insulin action [38].
Inflammation-mediated insulin resistance is characterized by the accumulation and
activation of macrophages and the other immune cells in the adipose tissue [39], and the
local activation of Kupffer cells in the liver [38,40]. Certain nutrients and metabolites (e.g.
free fatty acid, FFA) activate the cytokine-mediated pathways or the Toll-like receptor
(TLR) pathways in these immune cells, which in turn promotes the synthesis and
secretion of pro-inflammatory cytokines ( e.g. tumor necrosis factor α) [38,40]. The
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elevation of the pro-inflammatory cytokines in vivo causes systemic insulin resistance by
attenuating the insulin signaling pathway in a group of organs and tissues [38,40].
The cause and effect relationship between dysregulated lipid metabolism and
hyperinsulinemia is still unknown. However, it is generally accepted that the combined
effects of the two factors lead to increased circulating FFAs, and lipid accumulation in
the muscle and liver [38,41]. These excessive lipid molecules are considered “lipotoxic”,
which purportedly impact the insulin signaling cascade in the muscle cells and
hepatocytes, and exacerbate hyperglycemia and hyperinsulinemia [38,41].
The gut microbiota is the collection of all microbes/microbial genomes in the
gastrointestinal tract. It has been shown to influence the metabolism of the host in a
profound way [38]. Despite the fact that the cause and effect relationship between
dysregulated gut microbiota and metabolic disease is unknown, it is postulated that the
gut microbes impact the insulin sensitivity of the host by: (1) influencing the intestinal
immune system to produce pro-inflammatory factors; (2) producing metabolites (e.g.
short chain fatty acid or bile acid derivatives) that cause systemic inflammation [38].
2.3 Overnutrition and metabolic diseases
Both genetic and nutritional/environmental factors are instrumental to the
development of obesity and its related metabolic diseases [24,42]. Mutations in the
appetite-regulating

hormones

(e.g.

leptin

and

proopiomelanocortin)

and

their

corresponding receptors (e.g. leptin receptor and melanocortin 4 receptor, respectively)
result in early onset of obesity and obesity-associated metabolic dysregulations in both
humans and experimental rodents [43]. Given the increasing numbers of the monogenic
contributors, the majority of the obesity cases in human population are believed to be
polygenic [43]. On the other hand, overnutrition related to unhealthy eating habits
probably drives the rising global prevalence of overweight and obesity [44,45]. In spite of
the self-evident link between overnutrition and obesity, the underlying mechanisms that
the excessive intake of nutrients causes obesity and its related metabolic diseases have
not been fully understood.
The utilization of dietary macronutrients requires coordinative regulation of the
metabolic pathways in different organs and tissues of the body. In a fed state, excessive
dietary macronutrients are conserved in the forms of glycogen and TG for future energy
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needs. During fasting, glycogen and TG are respectively broken down into glucose and
fatty acids (FAs) to meet the energy needs of different organs and tissues in the body.
These processes are coordinately regulated by both hormonal and nutritional stimuli in
response to feeding and energy states so that the body reaches energy homeostasis
[24,42]. Dysregulated hormonal balance and nutrient metabolism not only disrupt the
energy homeostasis, but also predispose individuals to the development of obesity and its
related metabolic diseases [24].
Overnutrition provides not only excessive energy from macronutrients, but also
superfluous amount of vitamins and essential factors, which have regulatory roles. How
micronutrients such as vitamin A (VA, retinol) regulate the homeostasis of
macronutrients is still an ongoing research topic. As an essential and lipophilic
micronutrient, VA plays a key role in the general health of an individual [24]. The
following sections of Chapter I overviews the nomenclature, properties, metabolism and
major functions of VA, and also summarizes recent research progresses regarding the
roles of VA in carbohydrate, lipid and protein metabolism.

3. VA, carotenoids and retinoids
3.1 Provitamin A and preformed VA
VA is an essential lipophilic micronutrient, which is involved in a myriad of
important physiological functions, including vision formation, immune response, cell
differentiation and proliferation, embryonic development and metabolism [46]. Despite
its indispensable role in physiology, modern research leading to the discovery of VA
started in animal husbandry in the early 20th century. Pioneered by McCollum, Davis,
Osborne and Mendel [47], the respective findings of provitamin A and preformed VA
paved the way for the understanding of VA functions in human beings [48].
Provitamin A molecules (Figure 1-1, A) are mainly found in plant sources. The green
leaves of the majority of terrestrial plants contain carotenes — a group of important
photosynthetic pigment. In other yellow plant tissues and organs, cryptoxanthins can be
found besides carotenes. Both cryptoxanthins and carotenes are major sources of
provitamin A in the diets for herbivores and omnivores [49].
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A. Provitamin A

α-carotene

β-carotene

γ-carotene

cryptoxanthin

B. Preformed vitamin A

retinol

retinal

retinoic acid

Figure 1-1: Structures of representative molecules with VA activity.
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The isolation and characterization of carotene reveal three naturally occurring isomers,
which are named α-, β-, and γ-carotene, respectively. β-carotene is the most abundant
among the three isomers. It is also the most effective provitamin A in restoring growth
stunt of VA deficient (VAD) animals [49]. In comparison, α- and γ-carotene exhibit
about 25 to 50% of the activity of β-carotene [49]. Cryptoxanthins manifest 54 to 59% of
the activity of β-carotene [49].
Naturally occurring preformed VA (Figure 1-1, B) is derived from provitamin A.
Herbivorous and omnivorous animals convert provitamin A molecules into retinol in vivo,
and then store it as retinyl esters in different organs and tissues depending on the species
[50]. Retinol and retinyl esters are then introduced into food chain and transferred to
carnivorous and omnivorous animals at the higher tiers of the food chain [49].
Retinol can be enzymatically metabolized into different VA derivatives in vivo for
diverse physiological functions. Major derivatives include the aldehyde form of retinal,
the acid form of retinoic acid (RA) and retinyl ester (RE). For this reason, VA now
collectively refers to any compounds that exhibit the bioactivity of retinol regardless of
their origin [51].
3.2 Carotenoids and retinoids
The isolation and purification of β-carotene result in the discovery of a group of
pigments with similar structural and chemical properties, which are together termed
“carotenoids” [49] (Table 1-1). Xanthophyll from green leaves and lycopene from
tomatoes are two representative examples. In spite of the strong structural similarity, the
majority of carotenoids were physiologically inactive in alleviating VAD symptoms in
animals [49]. These carotenoids are not deemed provitamin A. Later research suggests
that they function as potent anti-oxidants [52].
Chemicals with similar structural properties to retinol, retinal and RA have also been
isolated from a variety of diets or synthesized from scratch for pharmaceutical purposes
in the past decades. For example, 3-dehydro-retinol (also known as vitamin A2) was
found in substantial quantities in some freshwater fishes [53]. This chemical is an
important dietary source of VA for some fish-eating animals, and it exhibits about 30%
activity of retinol [53]. Conjugated compound such as retinoyl β-glucuronide can be
found in vivo [51]. Additionally, RA analogues such as acitretin were synthesized to treat
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Table 1-1: List of common carotenoids in diets*.
Provitamin A

Carotenoids

Formula

α-carotene

C40H56

~25%

Green vegetables, red palm oil

β-carotene

C40H56

100%

Green vegetables, carrots

γ-carotene

C40H56

~25%

Green vegetables

cryptoxanthin

C40H55OH

54~59%

Yellow maize

xanthophyll

C40H54(OH)2

No activity

Green vegetables, egg yolk

lycopene

C40H56

No activity

Tomato

zeaxanthin

C40H54(OH)2

No activity

Yellow maize

astaxanthin

C40H52O4

No activity

Eggs, lobster

Activity

Dietary Source

* Adapted from Moore (1957), pp.70-71, 160-161.
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a series of diseases including acne [54], psoriasis [55] and cancer [56]. In order to
categorize this group of compounds, the term “retinoid” is coined. However, it is
important to point out that many retinoids lack the VA bioactivity [51].

4. Physical and chemical properties of VA
4.1 Structural properties of VA
Molecules with VA activity and their derivatives share common structural
components, including a β-ionone ring, an isoprenoid side chain, and a polar moiety
attached to the end (Figure 1-1, B).
Due to the presence of five conjugated double bonds in the isoprenoid side chain, VA
molecules can exist as intra-convertible cis- or trans- isomers. The most elucidated
example is the photoisomerization of 11-cis-retinal into all-trans-retinal in the rod and
cone cells. The photon-driven isomerization process provides the basis for the vision
cycle in both invertebrate and vertebrate animals [57]. Additionally, in some fish species
up to 30% of retinol exists in the cis- form [49]. Furthermore, when the pure cis- form of
retinol is used to treat VAD rats, about 89% of the VA reserve is later found in the transform in the liver. Similar result is also observed if the trans- form of retinol is
administered as the only source [58]. These observations suggest the existence of a finetuned mechanism in balancing the composition of VA isomers in vivo. Given the
difference in the spatial arrangement of chemical groups, the cis- and trans- VA isomers
exhibit different biological activity. Growth tests in rats show that cis- retinol and RE
isomers have about 25-75% of the activity compared with their trans- isomer
counterparts [59].
The polar end of the VA molecule is labile to chemical modifications, which
determine the physiological functions of the compound [46,60]. In the vision cycle, alltrans-retinol needs to go through esterification, isomerization and oxidation to form the
11-cis-retinal, which binds to opsin with high affinity via a Schiff base [57,60]. This
demonstrates that the oxidation state and the chemical modification of the VA greatly
affect its function in vivo. For the storage of retinol, the hydroxyl group of retinol is
esterified with a long chain FA, so that the resulting REs can be accumulated in the
stellate cells in the liver [51,60].
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4.2 Physical-chemical properties of VA
The β-ionone ring and the isoprenoid side chain grant the VA molecules with high
hydrophobicity, meaning that they are fat-soluble molecules. However, the presence of
the polar moiety facilitates VA molecules and their derivatives to show detergent-like
characteristics.
In aqueous environment, amphipathic molecules will associate with each other to
form micelles. This phenomenon is observed in most VA molecules and their derivatives
[51]. Especially, RA has a strong polar carboxyl group, which determines its relatively
higher solubility in water compared to its counterparts. Free RA forms micelles at the
micromolar concentration level [61]. Retinol and its derivatives usually bind to proteins
in vivo. This is to prevent forming micelles, which are disruptive of the cell membrane
and cell function [62].
4.3 Chemical properties of VA
The abundance of double bonds in the VA molecule structure determines its
susceptibility to oxidation and photodegradation [49]. In the open air, VA is quickly
oxidized into retrovitamin A, anhydrovitamin A and isoanhydravitamin A [63]. In the
organic solvents, the oxidation rate of VA is slower but steady. Comparably, VA will
remain stable for a longer time in natural fats due to the presence of antioxidants (e.g.
tocopherols) [49].

5. The absorption, transport and metabolism of VA
5.1 General information about the digestion and absorption of VA molecules
Dietary VA molecules are released from the digested food matrix in the
gastrointestinal tract (Figure 1-2). Due to their lipophilic characteristic, VA molecules are
incorporated into lipid micelles in the intestinal lumen prior to the absorption. The
formation of lipid micelles is an important step, in that bile and dietary fat have been
shown to facilitate the optimal absorption of VA molecules [49]. Additionally, lecithin
and vitamin E aid the absorption of VA molecules [49]. The former is a fantastic
emulsifier which improves the emulsification of fat droplets, and the latter protects VA
molecules from oxidation in the small intestine [64].
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Figure 1-2: Schematic graph of the digestion, transport and absorption of molecules
with vitamin A activity. Please see sections 5.1 through 5.4 for description. BB-REH,
brush-border retinyl ester hydrolase; LRAT, lecithin:retinol acyltransferase; ARAT, acylCoA:retinol acyltransferase; CRBP, cellular-retinol binding protein; RBP, retinol binding
protein; STRA6, stimulated by retinoic acid 6.
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Under similar conditions, the absorption of preformed VA molecules is more efficient
than that of provitamin A molecules. Experiments in rats show that more than 50% of
provitamin A molecules could be passed into feces and subsequently lost [65]. Therefore,
to obtain equal efficacy in treating VAD symptoms, it is suggested that twice the amount
of provitamin A molecules is needed compared to that of retinol [49].
5.2 The uptake of VA molecules into enterocytes
Once in the lipid micelles (Figure 1-2), dietary REs are hydrolyzed into retinol and
FAs by the brush-border retinyl ester hydrolase (BB-REH) in the intestinal lumen [66,67].
This enzyme is activated by bile salts and plays a central physiological role in converting
RE into retinol in vivo [66]. Then retinol is taken up into the enterocytes (intestinal
mucosal cells) by a transporter located at the brush border membrane [68]. This
membrane-bound retinol transporter is specific to the all-trans isomer, and its function
can be inhibited by the cysteine modification agent N-ethylmaleimide [68]. These results
suggest that retinol is absorbed via facilitated diffusion. In comparison, carotenoids enter
enterocytes via passive diffusion, which does not require transporter or energy [69,70]
Several studies also look at the absorption of supplemented retinol, retinal and RA
drugs in experimental rodents. The results show that the majority of supplemented retinol
and retinal are taken up by the enterocytes, and subsequently converted into RE [71]. In
the contrary, 92~95% of supplemented RA is secreted into the bile [71]. Depending on
the isomerization of the molecule, variable small amount of RA can be absorbed, and
later, released into the portal vein as free RA [71,72].
5.3 The fate of retinol and β-carotene within enterocytes
The intracellular metabolism of carotenoids in the enterocytes is a key step to
generate retinol in animals. Because of its relative abundance in food, β-carotene is the
most studied carotenoid in terms of absorption and metabolism. In human the majority of
β-carotene in the enterocytes will be symmetrically cleaved by 15,15’-dioxygenase to
generate retinal [73]. Residual intact β-carotene can be delivered to the liver, where the
same enzyme in the hepatocytes catalyzes the same cleavage reaction [70]. Even though
15,15’-dioxygenase was discovered about 50 years ago, the cloning of the corresponding
gene was not successful until recently [74]. Functional analysis of the gene confirmed its
primary expression in duodenal enterocytes and hepatocytes, consolidating its
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predominant role in metabolizing β-carotene [75]. Aside from the symmetrical cleavage,
β-carotene can also be asymmetrically cleaved at the 9’,10’ double bond by a specific
enzyme in the enterocyte [76,77].
The resulting retinal from the cleavage of the β-carotene is readily reduced into
retinol by a microsomal enzyme, retinal reductase [78]. Due to their limited solubility in
the cytosol, both retinol and retinal need to bind to cellular-retinol binding protein II
(CRBP II) to participate in this enzymatic reaction [79]. The generated retinol converges
into the retinol repertoire that comes from the hydrolysis of dietary REs [78].
From this point on, the majority of retinol needs to be reesterified with FAs (usually
palmitate). This key reaction converts retinol back into RE so that it can be incorporated
into chylomicron for the transportation to the liver [78]. It is noteworthy that free retinol
and RA can be directly secreted into portal circulation for transportation [78].
Two enzymes have been identified to possess the capability of reesterfying retinol in
vitro: lecithin:retinol acyltransferase [80] (LRAT) and acyl-CoA:retinol acyltransferase
[81] (ARAT). Both enzymes are associated with the microsomal fraction of the
enterocytes, but only LRAT manifests substrate preference to CRBP II-bound retinol [60].
This suggests that LRAT plays a more important role in the reesterification of retinol in
enterocytes [78].
5.4 The secretion, transportation and clearance of the RE containing chylomicrons
Chylomicrons formed in the enterocytes contain TGs, phospholipids, apolipoprotein
B48 (Apo B48), RE and other dietary lipophilic factors. Chylomicrons are secreted into
lymph, which enter circulation through thoracic duct at the subclavian vein. The first
experimental evidence for this phenomenon comes from ruminants and rats, in which the
majority of postprandial VA molecules are observed in lymph instead of portal blood
[82]. Additionally, pharmaceutical inhibition of chylomicron secretion by Pluronic L81
decreases RE secretion in Caco-2 cells [83]. In the same cell line, experiments show that
only newly synthesized RE will be incorporated into the nascent chylomicrons. This
demonstrates that RE synthesis and incorporation into the chylomicron are highly
concerted and regulated [84].
In the circulation, chylomicrons interact with lipoprotein lipase (LPL) at the inner
lining endothelial cells of the vascular system, which gradually hydrolyzes the TGs on
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the chylomicrons. This process decreases the size of the chylomicrons and converts them
into chylomicron remnants. Chylomicron remnants at the same time will take up
apolipoprotein E (Apo E) from the plasma, which is an important factor assisting the
hepatic clearance of the RE containing remnants [85]. In human and other animal species,
plasma cholesteryl ester transfer protein (CETP) is able to transfer small amount of RE
from chylomicron to low density lipoprotein (LDL) and HDL [86,87]. These transferred
RE molecules will be cleared by the liver with its associated lipoproteins.
After entering the space of Disse, the RE containing chylomicron remnants are
cleared by the hepatocytes via several parallel mechanisms [85]. The initial interaction of
the RE containing chylomicron remnants with the hepatocytes is mediated by the heparan
sulfate proteoglycans (HSPGs) located on the surface of the hepatocytes [88]. Then other
cell surface receptors including LDL receptor (LDLr), LDL receptor related protein
(LRP) and lipolysis-stimulated receptor (LSR) will bind to the Apo E on the chylomicron
remnants, which in turn facilitate the endocytosis in the hepatocytes [85].
After the hepatocytes endocytose chylomicron remnants, the REs are hydrolyzed into
retinol by the carboxylesterase ES-2 on the plasma membrane [89-91]. In the nascent
endosomes, this enzyme is shown to colocalize with REs, and its activation did not
require bile salts [92]. The formed retinol will then bind to cellular retinol binding protein
I (CRBP I) for the subsequent metabolism in the hepatocytes [93].
5.5 The storage and metabolism of VA in the liver
Even though VA is fat soluble, white adipose tissue itself is not determinant player in
the accumulation of VA [49]. In mammals, the liver is the primary storage site for REs,
whereas minor storage can be found in the adipose tissue, lung and kidney [94]. In chow
fed rats, 95~99% total hepatic retinol exists in the form of retinyl palmitate, and the total
hepatic retinol concentration is estimated to be 2.6 nmol

mg protein-1 [93,95].

Histological studies show that hepatic RE reserve is in a dynamic equilibrium between
stellate cells and hepatocytes (Figure 1-3). Depending on the VA status of the animal,
5~30% RE can be found in the hepatocytes, while the rest is stored in the stellate cells
[93,95].
The formation of CRBP I bound retinol in the hepatocyte greatly facilitates the
storage of retinol in the liver [90]. When dietary VA intake exceeds the physiological
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Figure 1-3: Schematic graph of the storage and metabolism of VA. Please see
sections 5.5 through 5.7 for description. ROL, retinol; RAL, retinal; RA, retinoic acid;
RE, retinyl ester; LDLr, low density lipoprotein receptor; LRP, LDL receptor related
protein; ES-2, carboxylesterase; CRBP, cellular-retinol binding protein; CRABP, cellular
retinoic acid binding protein; RDH, retinol dehydrogenase; RALDH, retinal
dehydrogenase; ER, endoplasmic reticulum; RBP, retinol binding protein; TTR,
transthyretin; RBPR2, retinol binding protein receptor 2; REH, retinyl ester hydrolase;
LRAT, lecithin:retinol acyltransferase.

17

need, the holo-CRBP I in the cytoplasm is continuously delivered to the endoplasmic
reticulum of the hepatocyte, where retinol binding protein 4 (RBP4) is actively
synthesized [96]. Retinol will be transferred from CRBP I to RBP4 so that it can be
secreted and transferred to the adjacent stellate cells. Within the stellate cells, LRAT
esterifies retinol (also bound to CRBP I) back into RE, which is finally stored in the large
cytoplasmic lipid droplets [94,97]. When the extrahepatic tissue is in need of VA, the RE
reserve in the stellate cells can be mobilized by lysosomal REH, which produces free
retinol [91,98]. The retinol will be bound to RBP4 and secreted into the circulation.
Compared with stellate cells, hepatocytes also maintain active metabolism of retinol.
On one hand, small amount of retinol can be esterified by hepatic LRAT and stored in
local lipid droplets [99]. On the other hand, hepatic retinol dehydrogenases (RDHs) and
retinal dehydrogenases (RALDHs) can metabolize retinol into retinal and RA, which
satisfies the local usage [94]. Depending on the physiological need in the body, it is
postulated that CRBP I regulates the homeostasis between retinol esterification and
metabolism [100]. Experiments in rodents show steady total CRBP I level in the liver
regardless of the VA status in the animal [100]. It has been shown that Apo-CRBP I
promotes RE hydrolysis and inhibits retinol esterification [101,102]. These evidence
suggest that the ratio of holo-CRBP I/apo-CRBP I indicates the cellular retinol status and
determines the route of its metabolism [100].
5.6 The delivery of retinol to extrahepatic tissues
The delivery of hydrophobic retinol to extrahepatic tissues is accomplished with the
assistance of plasma transport proteins, RBP4 and transthyretin (TTR). RBP4 is a small
protein expressed in a wide range of tissues and organs, including liver, adipose tissue,
kidney and muscle [94]. The circulating level of RBP4 has been associated with insulin
resistance in obese and diabetic individuals [103,104]. Its structure contains a
hydrophobic pocket that binds to one molecule of retinol [105]. In the circulation, RBP4retinol complex is associated with TTR, which blocks the exit site of retinol in RBP4 and
presumably prevents the filtration loss of the vitamin in the kidney [94,106].
Once the RBP4- retinol-TTR ternary complex is delivered to the peripheral target
cells, RBP4 is proposed to interact with the extrahepatic retinol transport protein STRA6
(Stimulated by retinoic acid 6) in the cell membrane. The interaction directly mediates
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the uptake of retinol into the cell without RBP4 being endocytosed [107]. Further
investigation shows that TTR does not affect the STRA6-mediated retinol uptake [107].
Additionally, the expression of STRA6 can be found in different embryonic development
stages and in a variety of adult organs and tissues except the liver [107]. STRA6
expression can also be up-regulated by RA in certain cancer cell lines [108]. These data
suggest that the uptake of retinol into target cells is not through passive diffusion, but
through a highly controlled process [107].
However, more recent studies have argued against the necessity of STRA6 as a
retinol transporter. Experiments with HepG2 and 3T3-L1 cells show that the transport of
retinol from RBP4 to CRBP I by STRA6 is linked to the activation of Janus kinase
(JAK)/Signal Transducer and Activator of Transcription (STAT) pathway within the cell
[109]. Furthermore, TTR is shown to block the activation of JAK/STAT pathway via
interfering with the RBP-STRA6 interaction [110]. These results suggest that STRA6 is
not a necessary retinol transporter, but a sensor of holo-RBP in the circulation [110].
5.7 Re-uptake of VA into hepatocytes
Unused retinol by the peripheral tissues will be eventually brought back to the liver,
where hepatocytes re-uptake retinol from the circulation. This process is mediated by the
RBP4 receptor 2 (RBPR2), a specific liver retinol transporter sharing high homology
with STRA6 [111]. Interestingly the expression of RBPR2 is suppressed by RA. Its
expression is also negatively correlated to the hepatic VA storage [111]. These results
suggest that the re-uptake of retinol in the liver plays a critical role in the overall VA
homeostasis and metabolism.

6. VA Status assessment and VA dietary recommendation
6.1 VA status assessment in human
The assessment of VA status in human body is mainly focused on two major VA
reserves: the RE reservoir in the liver and the circulating retinol in the plasma [49].
The hepatic RE content is considered the best indicator of VA status, since more than
90% of total VA molecules are stored in the liver [49]. By analyzing liver samples of
healthy individuals who died from accidents, Moore determined the median VA reserve
was 324 IU per gram of liver tissue. If the average weight of an adult liver is 1,500 grams,
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the total liver VA reserve is estimated to be around 500,000 IU [49]. Despite the
usefulness of the liver VA content in medicine, two obstacles hinder the application of
the measurement: one being the difficulty in obtaining liver samples, and the other being
the huge between-individual variance [112].
In early 1930s, a non-intrusive indirect procedure called dark adaptation test was
devised to determine moderate degrees of VA deficiency [113]. This procedure measures
how quickly a person adapts to darkness once the vision cells are light-bleached. In the
event of VA deficiency, the adaptation time is significantly longer and the threshold of
illumination used to illicit night vision is significantly higher [113]. Dark adaptation test
is widely accepted in the clinics, but it is less successful to identify subclinical VA
deficiency, which is believed to be more prevalent in the population [114].
As the high performance liquid chromatography (HPLC) tools become available in
the clinical settings, measurements of the circulating retinol or RBP4 concentration have
been used to determine the VA status in large populations [114]. According to the data
collected in the Health and Nutrition Examination Surveys, vitamin A sufficiency is
defined as the plasma retinol level above 1.05 µmol/L, whereas VA deficiency is defined
as the plasma retinol level less than 0.7 µmol/L [115]. Despite its wide application, the
plasma retinol level has its drawback in determining VA status. The reason is that serum
retinol concentration is tightly controlled within a small physiological range, and it does
not decrease until the liver storage is depleted [114,116]. Additionally, serum RBP4 level
has been shown to decrease in light of acute infections [117]. These drawbacks suggest
that serum retinol concentration is most useful in assessing VA status in those who
chronically have low VA intake.
In the last two decades, a novel approach termed relative dose response test (RDR)
has been developed to indirectly evaluate hepatic VA storage. This approach is based
upon the fact that exogenous VA molecules are stored in the liver under VA sufficient
(VAS) condition, but are mobilized into circulation under VAD condition [114,116]. In
this approach, a large dose of retinol, retinyl palmitate or retinol derivative (e.g. 3,4didehydroretinol) is given to the recipient, whose serum retinol concentration is measured
before the drug administration. Five or six hours later, the recipient is subjected to
another serum retinol concentration measurement. Then the percentage increase of serum
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retinol concentration over baseline is determined ((Retinol5h-Retinol0h)/Retinol0h × 100%).
A value greater than 20% indicates the suboptimal intake of VA [118]. Even though this
approach does not measure the total hepatic RE storage, it is proven to be able to reflect
the hepatic VA status with high fidelity [118].
6.2 VA deficiency and hypervitaminosis A
The lack of VA in the body is termed VA deficiency, which manifests itself in an
array of clinical symptoms, including growth stunt, loss of appetite, weight loss, impaired
immunity, night blindness, anemia and xerophthalmia [116]. These clinical consequences
are defined as vitamin A deficiency disorders (VADD), which affect millions of children
and adults around the globe [119,120]. Particularly in the developing world, VADD
remain a big nutrition and public health problem despite the huge advances in the health
care service in the past decades [119,121].
The primary cause of VA deficiency is the suboptimal intake of VA. However, many
diseases may also cause VA deficiency by decreasing physiological utilization of the
nutrients from the diet [116]. The development of VA deficiency is a chronic process.
Early clinical signs start to show up when the liver VA concentration drops below 10
µg/(gram tissue) [122]. As the deficiency progresses, more severe symptoms will appear.
Due to the barriers of obtaining the liver VA concentration, clinical characterization of
VA deficiency is established as the plasma retinol level below 0.7 µmol/L [115], or a
RDR value above 20% [118]. Once the deficiency is confirmed, large doses of VA
supplementation over a few weeks is necessary to bring back the liver VA reserve and
stop the progression of VA deficiency [123].
VA toxicity denotes the adverse effects caused by the excessive amount of VA in vivo
[124]. The toxic effects can come from both acute and chronic overdose of the vitamin.
Acute VA toxicity is a transient effect caused by doses of VA greater or equal to 150,000
µg over a short period. It is identified by nausea, vomiting, headache, vertigo, increased
cerebrospinal fluid pressure and blurred vision [125]. In the contrary, chronic VA toxicity
is caused by doses of VA greater or equal to 30,000 µg/day for months or years. It is
associated with increased risk of developing bone fracture, which often occurs unnoticed
[124]. Since serum retinol level is tightly controlled within a small range, it is particularly
difficult to assess the VA status in people with VA subtoxicity or toxicity. Therefore, new
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diagnostic methods are needed for the assessment of VA status in the well-nourished
individuals.
6.3 Dietary recommendation of VA in human
Determining the recommended daily dietary VA intake in human is a challenging task,
owing to many aspects of the vitamin in relation to food and human physiology [49].
First, dietary VA comes from both plant and animal sources. Depending on the presence
of dietary fat, food processing method, food matrix and potential nutrient-nutrient
interaction, dietary VA in different food items has different availabilities and absorption
efficiencies [49]. Second, human liver VA storage differs greatly among well-nourished
individuals. It is, therefore, difficult to decide a single liver storage value to deduce the
recommended daily intake for the whole population [49]. Third, the daily requirement of
VA is influenced by age, sex, diseases, pregnancy and lactation. The recommended daily
intake should be adjusted for those factors in the practice [49].
In order to evaluate and compare the availability of VA from different sources,
Institute of Medicine (2001) introduces retinol activity equivalent (RAE) to substitute the
previous used international unit (IU). One RAE is defined equal to 1 µg retinol, or 2 µg
supplemental β-carotene. If β-carotene is obtained from dietary sources, the equivalent
dose is set at 12 µg. All other provitamin A carotenoids share an equivalent dose of 24 µg
to 1 RAE. This standard makes it possible to determine the dietary VA intake from
different individuals and establish the recommendation for the population.
Since it is difficult to decide daily VA intake recommendation based on the total
hepatic VA reserve, Institute of Medicine utilized a computational method to derive the
estimated average requirement (EAR) of VA, such that the amount maintains the
adequate stores in the liver of well-nourished individuals. The mathematical formula and
the corresponding values for the variables are listed in Table 1-2. This formula results in
an EAR of 627 µg RAE per day for adult man and 503 µg RAE per day for adult woman.
To account for individual variance and ensure 97% of the population ingest adequate
amount of VA, recommended dietary allowance (RDA) for VA is set at 900 µg RAE per
day for adult man and 700 µg RAE per day for adult woman.
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Table 1-2: Calculation of EAR of vitamin A for adult*.

EAR × F = A × B × C × D × E
Letters

Meaning

Value

A

Percent of vitamin A stores lost per day on vitamin Afree diet

0.5%

B

Minimum liver vitamin A reserve without adverse
effects

C

The liver/body weight ratio

D

Reference weight

E

Total body vitamin A/liver vitamin A ratio

10:9

F

Efficiency of storage of ingested vitamin A

40%

20 μg/g tissue
1:33
76kg for male
61kg for female

* Adapted from IOM (2001)
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7. VA, retinoid signaling pathway and gene transcription
7.1 Overview of the retinoid signaling pathway
The importance of VA is well recognized in the regulation of a myriad of biological
events. The investigation of its pleiotropic effects in animals resulted in the discovery of
the retinoid signaling pathway, by which VA exerts its function by modulating gene
expression in target cells (Figure 1-4) [126,127]. In general, retinol is reversibly oxidized
into retinal by RDHs, and then, retinal is further irreversibly oxidized into RA by
RALDHs. RA molecules move to cell nucleus, where they interact with transcription
factors to regulate the down-stream gene expressions. It has been generally believed that
RA mainly binds to and activates two subfamilies of nuclear receptors (NRs), retinoid
acid receptors (RARs) and retinoid X receptors (RXRs). Specifically, all-trans-RA is an
exclusive ligand for RAR, whereas 9-cis-RA is a common ligand for both RAR and RXR
[128]. RARs and RXRs can recognize short consensus DNA sequences, which are termed
retinoic acid response elements (RAREs), located in the promoter region of RA
responsive genes. Depending on the specific gene, RXRs can bind to RARE in a
homodimer or a heterodimer with RARs or other NRs. In addition to RARs and RXRs,
RA signals have been suggested to be mediated by other NRs, such as peroxisome
proliferator-activated receptor (PPAR) β/δ, hepatocyte nuclear factor 4α and chicken
ovalbumin up-stream transcription factor II [24]. The binding of the NR dimers by their
ligands will help recruit corresponding transcriptional coactivators, dissociate
transcriptional corepressors, and interact with the general transcription machinery,
leading to the regulation of target gene expression.
7.2 Generation of retinoic acid in target cells
Given the importance of VA in different aspects of physiology and its hydrophobic
property, the generation of RA is a highly regulated process involving complex retinoid
binding proteins and metabolic enzymes [100].
RDHs catalyze the first step in the biosynthesis of RA, by which retinol is oxidized
into retinal. This reversible reaction has a low Vmax value, which makes it the rate
limiting step in the generation of RA [129]. In vitro biochemical experiments have so far
identified almost a dozen enzymes with retinol oxidation capabilities, but only RDH1,
RDH10 and DHRS9 (dehydrogenase/reductase member 9) are verified and supported by
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Figure 1-4: Schematic graph of the retinoid signaling pathway. Please see section 7.1
for description. ROL, retinol; RAL, retinal; RA, retinoic acid; RBP, retinol binding
protein; RBPR2, retinol binding protein receptor 2; CRBP, cellular-retinol binding
protein; CRABP, cellular retinoic acid binding protein; RDH, retinol dehydrogenase;
RALDH, retinal dehydrogenase; RARE, retinoic acid responsive element; RXR, retinoic
X receptor; RAR, retinoic acid receptor.
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in vivo evidence (Table 1-3) [100]. Early cell fractionation data suggest that most retinalgenerating capacity are associated with microsomes [130], showing the presence of
RDHs in the ER of intact cell. This is confirmed by the discovery of a short signal
sequence in the N-terminus of RDH, which can anchor the enzyme in the ER with the
catalytic domain facing toward the cytoplasm [131]. The catalytic property of RDH does
not require CRBP I, despite that the majority of retinol in the cell are bound to it [132].
One explanation is that CRBP I acts as a chaperone and facilitates the transfer of retinol
to enzyme [132].
The irreversible conversion of retinal into RA is catalyzed by RALDHs. Currently, four
RALDHs have been identified, which are expressed and regulated in a tissue specific
manner (Table 1-4). RALDH1 is universally expressed in tissues and accounts for over
90% retinal oxidation capability in rat liver and kidney [133]. Despite its ubiquitous
expression profile, RALDH1 knockout mice do not manifest developmental difference
compared to their wild type counterparts [134]. However, functional defects in certain
organs and tissues are observed in RALDH1 null mice. At 6 to 9 months of age RALDH1
null mice develops cataract, showing its critical role in the production of RA in the eye
[135]. Additionally, RALDH1 suppresses PPARγ and RXR responses in rodent fat,
which suggests that it is a key modulator of adipogenesis [136]. RALDH1 null mice are
resistant against high-fat diet induced glucose intolerance and obesity [136,137]. Multiple
studies in mouse hepatoma cells also provide evidence that RALDH1 expression can be
down-regulated by all-trans-RA, suggesting the presence of a negative feedback loop in
the generation of RA in vivo [138,139]. In contrast to RALDH1, RALDH2 knockout
mice are embryonically lethal. This suggests that RALDH2 is responsible for the local
production of RA during embryo development [140]. RALDH3 does not recognize 9-cisretinal as a substrate, whereas RALDH4 only recognizes 9-cis-retinal as a substrate
[141,142]. The selective recognition of substrates suggests the distinct functions of the
two enzymes in vivo, however, more research is necessary to elucidate the underlying
mechanisms [141,142].
The catabolic cytochrome P450 (CYP) family enzymes partially contribute to the RA
homeostasis. These enzymes require NADPH and oxygen to convert RA into a myriad of
end products, including 4-hydroxy-RA, 4-oxo-RA and 18-hydroxy-RA [143]. A
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Table 1-3: List of physiological relevant RDHs*.
Mouse gene

Orthologs

Tissue Distribution

Functions

Mouse Models

RDH1

Rat: RDH7, RDH2
Human: RDH16

Widespread

• atRA generation
• Metabolism
• Immune function

• RDH1 null mouse on chow diet
shows no developmental
phenotype
• RDH1 null mouse on vitamin A
restricted diet has increased body
weight and adiposity.
• RDH1 mRNA is decreased in Tg26
(HIV-1) mouse.

RDH10

Rat: RDH10
Human: RDH10

RPE cell, Müller cell
Dendritic cell
Early embryo

• Vision cycle
• Immune response
• Embryogenesis

• RDH10 null mouse is embryonically
lethal.

DHRS9

Rat: DHRS9
Human: DHRS9

Zebrafish embryo
Human colon
Human epidermis

• Embryogenesis
• Suppress
tumorigenesis

• No knockout available

* Adapted from Napoli (2012) and Kumar et al. (2012)

27

Table 1-4: List of physiological relevant RALDHs*.

Gene Name

Alternative Name

Tissue
Distribution

Functions

Mouse Models

RALDH1

Aldh1A1

Widespread

• ~90% atRA
generation
• Vision
• Metabolism

• RalDH1 null mouse develops
normally, and is fertile.
• RalDH1 null mouse develops
cataract.
• RalDH1 null mouse is resistant to
high-fat diet induced glucose
intolerance and obesity.

RALDH2

Aldh1A2

Widespread,
enriched in testis

• Embryogenesis

• RalDH2 null mouse is
embryonically lethal.

RALDH3

Aldh1A3

Widespread during
embryogenesis

• Embryogenesis
• Suppress
tumorigenesis

• RalDH3 null mouse develops
choanal atresia and is lethal at
birth.

RALDH4

Aldh1A4

Early embryo, liver, • To be determined
kidney

• Not available

* Compiled from Napoli (2012), Kumar et al. (2012) and Lin et al. (2002)
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representative member of the family, CYP26A1, is cloned and investigated for its role in
the regulation of RA homeostasis in animals [144-146]. CYP26A1 level is low in VAD
animals, but is substantially induced by RA or a VAS diet [145]. CYP26A1 null mice are
embryonically lethal, showing the phenotypes similar to wild type mice with excessive
RA [147]. These data show an autoregulatory mechanism by which CYP26A1 controls
RA catabolism to maintain RA level in vivo.
Most naturally occurring VA molecules in the diet and their metabolites are the alltrans isomers. The discovery of 9-cis-RA as the preferred ligand for RXR raises the
possibility of a 9-cis-RA metabolic pathway in vivo. However, the information on this
subject thus far is still limited. First of all, the detection of endogenous 9-cis-RA in
different tissues has been unconvincing except in pancreas, where 9-cis-RA acts as
autacoid to attenuate glucose stimulated insulin secretion [148,149]. Second of all, there
is no enzyme found to catalyze the isomerization of all-trans retinoids, except the system
in the vision cycle to produce 11-cis-retinal. Despite these, many studies tried to provides
explanations on how 9-cis-RA is formed in vivo. Urbach and Rando propose that the
isomerization of all-trans-RA into 9-cis-RA is a non-enzymatic reaction, which requires
sulfhydryl group in the microsome [150]. In contrast, many studies supported a possible
separate enzymatic system for the generation of 9-cis-RA. 9-cis-β-carotene was shown to
serve as a precursor for 9-cis-RA in a ferret model [151]. This is consolidated by the
discovery that 9-cis-retinal is the preferred substrate for RALDH4 [142], showing that it
is possible to generate 9-cis-RA in vivo.
7.3 RXRs and RARs
RARs and RXRs each have three subtype members, which are RARα, β, and γ, and
RXRα, β, and γ, respectively. Each subtype is encoded by a separate gene in the human
and rodent genomes. However, alternative splicing transcripts of one gene may generate
different isoforms for a subtype [152]. RARs and RXRs belong to the NR superfamily,
whose members share similar structural arrangements and functional domains (Figure 15). The A/B domain resides in the N-terminus of the receptors, and it contains the
activation domain I (AF-1) [153]. The AF-1 domain is necessary for the full activation of
the transcription activity of RARs and RXRs, but the activation process is autonomous
and ligand-independent [153]. Following the A/B domain in the structure resides the
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Figure 1-5: Schematic graph of (A) NR structures and (B )RARE in the promoter region.
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DNA-binding domain (DBD). The amino acid sequence of DBD is highly homologous
across the members of NRs. Two C4 zinc fingers organized into two α-helices interact
with the target DNA [154]. Within the DBD, a short peptide of three amino acids in the P
box differentiates and recognizes the RARE in the target DNA [155,156]. The ligandbinding domain (LBD) is linked to the DBD via a short hinge domain. The LBD is a
multifunctional domain which not only binds to specific ligands, but also helps the
dimerization of NRs and the binding to other transcriptional factors [127,157]. Notably,
the dimerization of NRs and the binding of the NRs to the DNA are a ligand-independent
process, whereas the binding of other transcriptional factors and achieving maximal
transcriptional activity require ligand binding [127,153,158].
Both RXRs and RARs recognize and bind to the RARE located in the promoter
region of a gene. Within RARE two consensus half sites (AGGTGA) are separated by a
spacer in the arrangement of either direct repeats, or palindrome, or inverted palindrome
(Figure 1-5) [159]. The RXR-RAR heterodimer can bind to those RARE arrangements
with different efficiencies. Depending on the RARE in the promoter region of the target
gene, the different binding efficiencies of the heterodimer confers a level of specificity in
the gene expression regulation [94,159].
7.4 Coactivators and Corepressors
The LBD domains in the RXRs and RARs are involved in the recruitment of
transcriptional coactivators and corepressors. Biochemical analysis of RXRs and RARs
shows that the LBD domains of apo-RXRs and apo-RARs interact with a conserved
motif (CoRNR) in the C terminus of corepressors [160]. Once the specific ligand binds to
the ligand pocket in the LBD, it induces a conformational change in the LBD domain,
where H12 α-helix forms a surface for coactivators to bind with other motifs [161].
Interestingly, this surface recognizes the LXXLL motifs in the structures of coactivators,
which shares great homology with the CoRNR motif in the corepressors [127,160]. These
results showed that the binding of coactivators and corepressors to the RXRs and RARs
are mutually exclusive [160].
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8. Major physiological functions of VA
8.1 VA and the vision
Thousands of years before Holm [162] and Yudkin [163] detected trace amount of
VA in the retina of farm animals, ancient civilizations around the globe had learned to
use VA enriched animal liver to treat night blindness by either ingestion or topical
treatment [47]. However, the puzzle pieces for the molecular mechanism of the vision
cycle were not found until 20th century (Figure 1-6). First, the trace amount of VA in the
retina was proved to exist mainly in the aldehyde form [164-166]. Second, the visual
pigment rhodopsin (also known as visual purple) was discovered [49]. Third and most
important, through a series of experiments Wald elucidated the enzymatic systems
required for the interconversion of cis- and trans- retinal and the formation of rhodopsin
in the eye [167]. The information helped establish the current picture of the vision cycle
involving retinal pigment epithelial (RPE) cells, photoreceptor cells (cone cells and rod
cells), and Müller cells in the retina.
Photoreceptor cells are specialized neurons with lamellar membrane structures in the eye.
These highly specialized structures contain transmembrane pigment rhodopsin and face
toward the microvascular network [57]. The RPE cells are specialized epithelial cells,
which separate the photoreceptor cells and the microvascular network. Their particular
cell polarity ensures the directional movement of nutrients from the blood to the
photoreceptor cells [57]. The Müller cells extend across photoreceptor cells, which
function as glial cells in the specialized neuronal system. However, recent investigation
suggests that they might as well participate the vision cycle in the cone cells [57].
The vision cycle starts with the rhodopsin located in the lamellar membranes of the
photoreceptor cells. In its stable state, rhodopsin is the protein opsin bound to 11-cisretinal via a Schiff base [57]. An exposure to light will isomerize the 11-cis-retinal to alltrans-retinal and give out the light neuronal signal. All-trans-retinal is subsequently
released from rhodopsin into the cytosol of the photoreceptor cells due to the
hydrolyzation of the Schiff base [57]. In vertebrate animals All-trans-retinal is reduced to
11-trans-retinol by RDH8 and RDH12 in the photoreceptor cells [168,169]. The latter,
secreted and bound to interphotoreceptor RBP (IRBP), is taken up by RPE cells in a
STRA6 mediated process [107]. All-trans-retinol in the RPE cells will bind to CRBP I so
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that it can be esterified by LRAT [170]. The retinyl ester is the substrate for the
isomerhyd retinol ase RPE65, which hydrolyzes the ester and produces 11-cis-retinol
[171]. 11-cis-retinol is then bound to CRABP I so that it can be oxidized into 11-cisretinal by 11-cis-retinol dehydrogenases (11-RDHs) in the presence of NAD(P )+. The
11-cis-retinal will be transported back to the photoreceptor cells to form rhodopsin,
thereby completing the visual cycle [57].
Apart from the participation in the visual cycle, VA is also critical for the normal
morphology of the cornea. Severe VA deficiency causes xerophthalmia, which has
affected people in the deprived areas and people having VA restricted diet in the world
[172,173].
8.2 VA and immunity
VA was initially named the “anti-infective” vitamin in 1928 for the observation of
impaired immunity in VAD animals and human beings [174]. Lung infection, epithelial
abnormalities, and kidney stones are among the most common manifestations [174].
However, recent studies have otherwise showed that infection could cause VA deficiency
[175]. Serum retinol level decreases in response to acute infection, whereas hepatic VA
storage quickly depletes during acute viral infection [176]. The mechanism of infectioninduced VA deficiency is postulated to be multifactorial [175]. Infection can (1)
dramatically change appetite and nutrient intake [177-179]; (2) disturb digestive system
and cause malabsorption [180,181]; (3) cause direct loss of nutrients via vomit, urine,
sweat, stool and other body secretions [182]; (4) dramatically increase daily nutrient
requirement by altering metabolism [175]; (5) dramatically decrease the cellular nutrient
utilizations [175]. These points suggest that VA mainly helps the recovery from infection,
rather than the prevention of infection in the first place [175].
VA deficiency compromises both innate immunity and adaptive immunity according
to experiments in rodent and observations in human. The integrity of mucosa, the first
defense in innate immunity, is poorly maintained in VAD individuals [183]. Additionally,
RA, the active form of VA, has been used clinically to treat promyelocytic leukemia,
which is a genetic disease characterized by defective neutrophil maturation [184]. In
rodents VA deficiency has been shown to increase macrophage number and the secretion
of proinflammatory cytokine IL12 [185]. In humans VA deficiency is associated with
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lower phagocytotic activity of microphages against gram positive bacteria [186]. The
evidence clearly shows that VA deficiency impairs multiple components of the innate
immunity.
Adaptive immunity is a pathogen-specific defense that requires B and T lymphocytes.
It is yet unclear how VA affects the functions of B lymphocytes, but sufficient evidence
has shown that VA is critical in regulating the differentiation of T lymphocytes into Th1
and Th2 cells [175,187]. Low VA status pushes the fate of naive T lymphocytes into Th1
cells, whereas high VA status generally promotes differentiation toward Th2 cells
[175,187]. The fine balance of Th1/Th2 cells in the body is postulated to affect
autoimmunity, anti-/pro-inflammation and antibody recognition, underlining the critical
role of VA in adaptive immunity [175,187].
8.3 VA and cell differentiation, proliferation and apoptosis.
In response to different hormonal and nutritional stimuli, cell differentiation,
proliferation and apoptosis coordinate in a temporal-spatial manner to maintain tissue
homeostasis, and to control growth and development [94]. Early documentation in animal
husbandry has shown that VA affects animal growth and development [188,189]. With
the discovery of the NRs, RA and other retinoids have been established as the effector
molecules in the regulation of growth and development [94]. The regulation is postulated
to occur at three different levels [94,190]: (1) the expression of hormones, cytokines and
growth factors; (2) the expression of corresponding receptors and binding proteins for the
hormones, cytokines and growth factors; (3) the expression of downstream genes in
different signaling pathways that control growth and development. The detailed
molecular mechanism by which RA regulates each specific gene expression may differ,
but the NRs mediated RA signals and the binding of retinoids to them are central to the
general mechanism of regulation [94,191].
In mammals, the dietary VA is required for the progression of spermatogenesis in
testis. Due to the blood-testis barrier and low absorption rate, RA supplementation is
unable to recover male sterility in VAD rats, suggesting the indispensable role of retinol
in spermatozoa differentiation [192]. Furthermore, male sterility is also observed in
strains of RARα, RARγ and RXRβ mutant mice, which manifest defects in different
stages of the spermatozoa differentiation [193-195]. Besides spermatogenesis, another
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well studied phenomenon is the effect of RA on the differentiation of myeloid leukemic
cells, including HL-60, THP-1 and U-937 [196,197]. Experiments have shown that RA
can specifically induce the differentiation of acute promyelocytic leukemic cells into
granulocytes, which provides the basis for the clinical treatment of promyelocytic
leukemia with RA [184].
RA affects the cell proliferation by modulating key regulators in the progression of
the cell cycle. In different cancer cell lines, RA treatment can up-regulate cyclindependent kinase (CDK) inhibitors, whereas down-regulate CDK and c-myc expression
[94]. This results in the accumulation of cells arrested at the G0/G1 phase in the cell
cycle, which showcases the anti-proliferative properties of RA [198]. Correspondingly,
NRs have also been implicated in the modulation of cell proliferation. For example,
RARβ has been shown to mediate the growth inhibitory effects of retinoids in many cell
lines, including fibroblasts [199], mammary epithelial cells [200] and neuroblastoma cells
[201]. In mammary carcinoma RARβ also depends on RARα and estrogen receptor (ER)
to confer the tumor suppressive effect [198], suggesting the crosstalk between signaling
pathways in the regulation of cell proliferation.
Apoptosis is the critical counterbalance against cell differentiation and proliferation in
the process of growth and development [202]. Even though the information is still limited,
several studies have shown evidence that RA is able to promote or inhibit apoptosis
depending on the system. In MCF-7 mammary carcinoma cells all-trans-RA is able to
induce apoptosis preceded by G1 arrest in the cell cycle [198]. In keratinocytes all-transRA acts as an apoptosis sensitizer instead of an apoptosis inducer, in that it increases the
expression of p53 and proapoptotic caspases [203]. On the contrary, in neuronal cells and
retinal cells RA shows anti-apoptotic activities to maintain cell survival [202].
8.4 VA and growth
VA was first recognized as an essential factor for animal growth. Following the
withdrawal of VA from the diet, growth retardation is the earliest and most reproducible
sign of deficiency in many experimental animals [204]. Rats fed a VAD diet upon
weaning (about three weeks old) manifest cessation of growth and significant weight loss
later on [205,206]. The reduction of body mass can be prevented by RA supplementation.
However, once RA is removed from those rats fed the VAD diet, the weight loss will
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reappear in a couple of days [189,207]. These demonstrate that VA is important for the
normal growth and development of animals.
In comparison to rats, mice are more resistant to the development of VA deficiency.
Normal growth curve is usually observed in weaning mice with sufficient hepatic VA
storage despite being sustained on a VAD diet [208,209]. In one study, significant weight
loss was achieved in mice fed a VAD diet only when the VA storage was pre-depleted
prior to weaning [208]. This suggests that mice might have special mechanisms to
maintain VA homeostasis or they might use VA more efficiently. As a result, experiment
conclusions obtained in mice cannot be directly extrapolated to rats or humans in terms of
VA and its effects on growth and metabolism.
8.5 VA and appetite, taste and olfaction
VAD animals exhibit decreased appetite and food intake during the period of growth
cessation [205,206]. The underlying molecular mechanisms by which VA regulate energy
intake remain elusive. Since leptin, an adipocyte-derived peptide hormone, exerts its
action in the brain to regulate appetite, energy expenditure and metabolism [210], some
research investigated the effects of VA on the expression of leptin in rodents. The results
showed that both RA treatment and VA supplementation were able to decrease leptin
mRNA expression in adipocytes, which, in turn, decreased the serum leptin levels
[211,212]. Interestingly, the energy intakes of these rodents did not change during the
course of VA supplementation [213]. These data suggest that the VA-induced decrease in
leptin levels does not correlate with the food intake in the animals [213].
VA has also been implicated in the normal functions of the taste and olfactory system.
VA depletion causes the loss of both preference to sodium chloride and aversion to
quinine in rats, and these abnormal responses could be restored by VA supplementation
[214]. One study also shows that the response to sweetness in the VAD rats is impaired
[215]. Furthermore, VA supplementation can improve the impairment of taste and
olfaction in patients with cirrhosis [216]. Despite these many observations, the
mechanism is not clear. Keratin infiltration into the taste buds is proposed as a
mechanism by which VA deficiency affects the taste in rats [214]. But the physical
change could not be confirmed in all VAD rodent models [215].
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9. VA and metabolism
9.1 VA and plasma parameters: clinical evidence
The association between VA and metabolism was discovered from the clinical
observations in human subjects with type 2 diabetes. Biopsies of the liver of diabetic
patients showed that the hepatic VA content was twice as much as that in healthy
individuals [112]. Independent studies carried out more than eighty years ago also found
that, about 85% of adult patients with type 2 diabetes had elevated carotene levels in the
plasma, and more than 10% of them were clinically diagnosed with xanthosis [217,218].
Similar results were obtained in a lesser degree in type 2 diabetic children, but their
plasma VA levels were found to be subnormal [219]. More recently, retinol binding
protein 4 (RBP4), a serum retinol transporter, was shown to be elevated in insulin
resistant and type 2 diabetic subjects [104]. Interestingly, reduction of serum retinol and
RBP levels was found in type 1 diabetic patients [220]. These data suggest that VA plays
important roles in the metabolic homeostasis.
The association between VA and plasma lipid metabolism was also observed in
patients taking retinoid drugs. Medical administration of isotretinoin (13-cis-RA) results
in hypertriglyceridemia in human subjects with acne [221]. Treatment of acute
promyelocytic leukemia with all-trans-RA leads to weight gain, and elevation of plasma
TG and cholesterol levels [222,223]. It is postulated that the dysregulated plasma lipid
levels are caused by the RA-induced apolipoprotein CIII expression [224].
Apolipoprotein CIII is regarded as an inhibitor of LPL activity [225]. In the contrary,
long-term administration of fenretinide, a synthetic retinoid drug currently under phase II
clinical trial, could prevent diet-induced obesity, insulin resistance and hepatosteatosis
[226,227]. As more and more retinoid drugs are synthesized and tested, it would be
interesting to see how they affect human metabolism in any given health condition.
9.2 VA and metabolism in the liver
9.2.1 VA and the hepatic carbohydrate metabolism
The liver plays a leading role in the regulation of carbohydrate metabolism in
response to the feeding and fasting statuses. Experiments in rodents show that both
hypervitaminosis A and hypovitaminosis A affect carbohydrate metabolism in the liver
[42].
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Glycogen is a crucial polysaccharide, in which intracellular glucose is stored. Hepatic
glycogen synthesis and degradation contribute to the plasma glucose homeostasis. In
VAD rats, the liver glycogen content is abolished due to decreased glycogenesis from
acetate, lactate and glycerol, rather than directly from glucose [228,229]. The decreased
glycogenesis can be recovered by the administration of glucocorticoid hormone [229].
Since VAD animals have lower adrenal steroid production, it is possible that VA
deficiency partially affects glycogen metabolism via decreasing glucocorticoid hormone
synthesis [229]. In hypervitaminotic A rats, the liver glycogen deposition in the fed state
is almost the same or slightly lower than that in rats fed a chow diet [230,231]. However,
the liver glycogenesis of hypervitaminotic A rats after 18 to 20 hours of fasting is
significantly higher than that in rats fed chow [231]. This suggests that excessive VA
intake for a short-term can prevent the hepatic glycogenolysis under the fasting condition.
Additionally, excessive VA can also enhance the hepatic glycogenesis from glucose after
refeeding in normal rats, but not in adrenalectomized rats [232]. This suggests that
adrenal hormones are involved in the VA-regulated hepatic glycogen metabolism [232].
Glycolysis is a series of enzymatic reactions, which break down glucose to produce
pyruvate and generate ATP and NADH. This important carbohydrate metabolic pathway
is influenced by VA status. In VAD hamster, the hepatic generation of glucose-6phosphate was decreased by up to 90% due to the reduced glucokinase (gene Gck)
activity [233]. Similarly, the generation of mannose-6-phosphate was also decreased due
to the impaired hexokinase activity [233]. In the contrary, hypervitaminosis A does not
affect the enzymatic activities of hepatic glucokinase and hexokinase [234]. Instead, the
excessive VA can decrease the enzymatic activities of phosphofructokinase and pyruvate
kinase [234]. Additionally, the Gck mRNA levels in the liver of the VAD rats are lower
than that of the VA sufficient counterparts [206]. Retinoids not only increases the hepatic
Gck expression in rats, but also synergize with insulin to induce Gck expression in
primary rat hepatocytes [235]. These observations suggest that VA is an important
regulator of hepatic glycolytic enzymes.
Gluconeogenesis is a series of enzymatic reactions, which utilize non-carbohydrate
substrates (e.g. lactate, pyruvate, amino acid) to generate glucose. This metabolic
pathway is very important in maintaining the fasting blood glucose level in animals.
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Experiments with VAD rats show that the enzymatic activities of glucose-6-phosphatase
and fructose-1,6-bisphosphatase were decreased in the liver, showing an inhibition of
hepatic gluconeogenesis [236]. Comparably, hypervitaminotic A rats have elevated
enzymatic activities of hepatic phosphoenolpyruvate carboxykinase (PEPCK, gene Pck1),
glucose-6-phosphatase and fructose-1,6-bisphosphatase [237,238]. In addition, the VAmediated increase in gluconeogenesis is abolished in adrenalectomized rats [239],
showing the requirement of adrenal hormones in the process. The regulation of
gluconeogenesis by VA can also occur at the transcription level of Pck1 expression in the
liver. RA not only induces the Pck1 expression in primary rat hepatocytes, but also
attenuates the insulin-suppressed Pck1 expression [240]. In fact, insulin can inhibit the
RA-activated RXRs, but not RARs in the Pck1 promoter. This mechanism underlies the
production of Pck1 mRNAs in the presence of RA despite in an insulin-suppressed state
[240]. Additionally, a Pck1 transgenic mice model shows that all-trans-RAs and 9-cisRAs differentially regulate the hepatic Pck1 expression in the periportal region of the
liver acinus [241]. This retinoid regulated Pck1 expression is purportedly mediated by
different RAREs and NRs at its promoter [241,242].
9.2.2 VA and the hepatic protein metabolism
Ever since the increased nitrogenous metabolism was first described in the VAD rats
[243], many animal models were used to investigate the effects of VA on protein
metabolism. In young male rats on a VAD diet, urinary nitrogen excretion is increased
with concurrent negative nitrogen balance [244]. It is in line with the observation of
increased plasma urea in the VAD adult rats [245]. Interestingly, these physiological
changes cannot be obtained in VAD female rats, indicating a sex difference in the effects
of VA on protein metabolism [246]. Additionally, VA deficiency increases both the
mRNA levels and the enzyme activities of most urea cycle enzymes in the rat liver [245].
These data suggest that VA deficiency increases protein catabolism by upregulating the
enzymes of the urea cycle in both the liver and kidney.
The effect of VA deficiency on protein anabolism is controversial. The analysis of the
incorporation rate of 14C-leucine into proteins in both VAD and chow-fed rats shows that
VA deficiency does not adversely affect protein synthesis [247]. However, in vitro
protein synthesis assay using isolated rat liver ribosomes shows the opposite effect. Cell
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precipitates from the pH 5.1 fraction of the VAD rat liver homogenate exhibits enhanced
protein synthesis capability [248]. The reason for these conflicting results is not known.
Very few studies looked at the effects of hypervitaminosis A on protein metabolism
in animals. It is proposed in one study that 400 times of normal dose of VA causes the
toxicity-induced weight loss and negative nitrogen balance [249]. However, the
molecular mechanism by which the VA toxicity offsets nitrogen balance in vivo is
unknown.
9.2.3 VA and the hepatic lipid metabolism
Dysregulation in the metabolism of either VA or lipid could negatively affect the
metabolism of the other. On one hand, long-term retinoid drug users and people who take
excessive amount of VA supplements exhibit symptoms of hypercholesterolemia,
hypertriglyceridemia and high serum low density lipoprotein levels [250-252]. On the
other hand, patients with severe hypertriglyceridemia associated with type V
hyperlipoproteinemia have increased risk for developing hypervitaminosis A [253]. The
mechanisms underlying these phenomena have been actively investigated in rodent
models. Oral administration of large doses of retinol leads to the accumulation of lipid
droplets in the rat liver [254]. Overdose of retinol or retinyl palmitate also causes the
elevation of hepatic cholesterol, FA, and TG contents in different strains of rats [255257].
It has been shown that hypervitaminotic A rats have increased rates of hepatic FA
oxidation and ketogenesis [257]. On the other hand, the hepatic TG synthesis rate is
greatly enhanced in the hypervitaminotic A rats. This is due to the increased
incorporation rate of palmitate into TGs and the formation of glycerophosphate from
glucose [256,257]. Interestingly, the rate of hepatic TG secretion is not changed in
hypervitaminotic A rats [258]. These data suggest that VA increases hepatic lipid
synthesis to an extent much greater than it elevates hepatic lipid oxidation. The net result
is the accumulation of lipid in the liver. Further investigation shows that the
hyperlipidemic effect of excessive intake of VA can not be observed in adrenalectomized
rats, showing the involvement of adrenal hormones [256].
In the contrary to the hyperlipidemic effect of hypervitaminosis A, VA deficiency
causes a partial hypolipidemic effect in rodents. In general, VAD rats have decreased
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hepatic phospholipid content and decreased serum levels of TG, cholesterol and HDL
[206,259]. Interestingly, these rats manifest unaltered hepatic contents of TG and
cholesterol [257,260-262]. Depending on the severity of VA deficiency in the animals,
not all the above-mentioned symptoms can be observed. The partial hypolipidemic effect
of VA deficiency in rodent may be caused by decreased FA synthesis activity in the liver
and impaired cholesterol synthesis from mevalonate [259,262]. However, it is worth
mentioning that the VA deficiency-induced body mass loss and food intake drop may
also contribute to the hypolipidemic symptoms. Evidence shows that the decrease in total
percentage of body fat is similar between the VAD rats and their counterparts pair-fed a
VA sufficient diet [263]. All the data suggest that the dyslipidemia in VAD and
hypervitaminotic A animals is a multicausal effect.
The hepatic FA synthesis is governed by an allotment of lipogenic genes, including
acetyl-CoA carboxylase (ACC, gene Acc) and FA synthase (FAS, gene Fas). The
transcription of hepatic Acc and Fas is controlled by a transcriptional factor termed
sterol-responsive element binding protein 1c (SREBP-1c, gene Srebp-1c) [264]. In
primary rat hepatocytes, insulin induces the Srebp-1c expression through transcription
factors associated to the liver X receptor elements in the Srebp-1c gene promoter [265].
Interestingly, the corresponding liver X receptor elements in the Srebp-1c promoter are
also identified as RAREs [266]. This finding provides a possible mechanism, by which
RA synergizes with insulin to induce the hepatic Srebp-1c expression [266]. It also
showcases how nutritional and hormonal converge at the transcription level to regulate de
novo FA synthesis in the liver.
9.2.4 VA and mitochondrial functions in hepatocytes
Mitochondrion is the powerhouse of an eukaryotic cell, within which tricarboxylic
acid cycle (TCA cycle) and coupled-oxidative phosphorylation together generate ATP for
physiological events. TCA cycle is a series of enzymatic reactions that generates
reducing equivalents (NADH and FADH2) by utilizing acetyl-CoA derived from
monosaccharide, amino acid and FA. The reducing agents ultimately provide electrons,
which are consumed in the coupled oxidative phosphorylation process to reduce O2 and
generate ATP and water.
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In the rodent liver, both hypo- and hypervitaminosis A are implicated in the
uncoupled oxidative phosphorylation in the mitochondria [267-269]. On one hand, the
oxygen consumption by liver homogenates of hypo- and hypervitaminotic A rats is
significantly increased upon the supply of some TCA intermediates [267,268]. On the
other hand, the capacity for the oxidative phosphorylation is severely impaired in the
liver mitochondria of hypo- and hypervitaminotic A rats without affecting the ATPase
activity [269]. These data suggest that deficient or excessive VA status may increase
basal energy metabolism in the liver.
9.3 VA and islets of Langerhans in the pancreas
Islet of Langerhans, which account for less than 2% of the total pancreas mass,
produces and secrets peptide hormones from five different types of specialized cells,
including α-, β-, polypeptide (PP-), δ-, and ε-cells [270,271]. Among all the hormones
produced by islets, glucagon from α-cells and insulin from β-cells are of great clinical
interest due to their concerted roles in the regulation of blood glucose and lipid levels.
Glucagon promotes hepatic glucose production, glycogenolysis and ketone production in
response to hypoglycemia, whereas insulin promotes glucose disposal, glycogenesis and
lipogenesis in response to the increase of plasma glucose level [272].
The secretion of glucagon is controlled by autonomous nervous system, direct actions
of glucose on α-cells, and indirect effects of paracrine factors from non-α-cells on α-cells
[273]. On the other hand, the secretion of insulin is mainly stimulated by the influx of
glucose into β-cells. Glucose metabolism in β-cells leads to the elevated ATP/ADP ratio,
which in turn, inhibits the ATP-sensitive potassium channels on the cell membrane. The
inhibition depolarizes the plasma membrane, which results in the secretion of insulin. In
addition to glucose, amino acid and neural stimuli can also stimulate insulin secretion
[274].
It has been shown that VA and its metabolites can affect the secretion of glucagon. In
the VAD rats, the impaired glucagon secretion occurs from early stage of the deficiency,
and the impairment cannot be rescued by RA replenishment [275]. This demonstrates a
critical physiologic role of VA in the normal function of α-cells. Interestingly, in the
isolated intact rat islets and glucagon secreting cell lines, both retinol and RA inhibit the
glucagon secretion in a dose-dependent manner [276]. This result suggests that the acute
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effects of VA on glucagon secretion in vitro do not correlate with its physiological effects
in vivo.
VA deficiency has been shown to decrease β-cell functions in rat in two ways. First, it
reduces the β-cell mass in fetal islets by reducing the fetal β-cell replication [277].
Second, it impairs the glucose-stimulated insulin secretion (GSIS) from β-cells [278]. In
comparison, the effects of VA and its metabolites on isolated islets and insulin secreting
cells are both chemical- and dosage-dependent. For example, retinol at 10-7M stimulates
GSIS from isolated rat islets, which is in opposition to the inhibitory effect of retinol at
10-4 ~ -5M [279]. Additionally, all-trans-RA potentiates GSIS [280-282], whereas 9-cisRA inhibits GSIS [148] from rodent islets and INS-1 cells. CRBP I knockout mice
exhibits increased level of 9-cis-RA in the pancreas and reduced GSIS [283]. It is also
observed that all-trans-RA induces the Gck mRNA level and enzyme activity of
glucokinase [282], whereas 9-cis-RA treatment is associated with decreased GLUT2 and
glucokinase activities in rodent islets [148]. Given the fact that retinoid receptors require
preferential ligands to exert full function, these results suggest that the production and
balance of RA and its metabolites are critical for the normal functions of β-cells.
9.4 VA and metabolism in adipose tissues
9.4.1 VA and metabolism in white adipose tissue
White adipose tissues not only store excessive energy as TGs, but also secrete
important adipocyte-derived hormones and cytokines to regulate whole body energy
metabolism. VA and its metabolites have determinant effects on the metabolic
homeostasis in white adipose tissue.
Firstly, VA status has been shown to affect adiposity in animals. In VAD rats, the loss
of body fat deposit mass is reflected in the decreased total body mass [244]. Since the
VAD rats have significantly lower body mass compared to their counterparts pair-fed the
VAS diet, it suggests that the reduction of fat mass in the VAD rats cannot be fully
attributed to the VA deficiency associated with the reduction of food intake [244]. In
Zucker lean rats, VA deficiency decreases the epididymal fat mass and its fat mass/body
mass ratio [206]. In Zucker fatty rats, a genetic rat model of obesity, VA deficiency
retards the development of obesity [206]. Additionally, hypervitaminotic A rats have
decreased release of FAs from white adipocytes, whereas VAD rats exhibit increased rate
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of lipolysis in white adipose tissue [284]. Despite these findings supporting VA’s role in
maintaining adiposity, other studies have reported different observations. Mice on a VAD
diet for 10 weeks show increased adiposity [285]. More importantly in humans, low
plasma VA status has been associated with overweight and obesity [286,287]. These
divergent data warrant further research into the relationship between VA status and
adiposity in animals.
Secondly, it has been reported that RA treatment induces lipolysis and depletes lipid
storage in mature white adipocytes, which leads to weight loss in diet-induced obese mice
[288]. All-trans-RA treatment also decreases white adipose tissue mass in healthy lean
mice [289]. The anti-obesogenic effect of all-trans-RA may be mediated through the
activation of PPARβ/δ and RAR, which are important factors in the upregulation of
energy dissipation [288]. It is also hypothesized that all-trans-RA promotes the
acquisition of brown adipose tissue-like properties in white adipocytes [289]. Indeed, alltrans-RA induces the expression of uncoupling protein 1 (UCP1), an mediator of adipose
thermogenesis, in mouse white adipocytes, possibly via the activation of RARs [290].
However, all-trans-RA has no effect, or even inhibits, the expression of UCP1 in human
white adipocytes [290]. These conflicting results suggest that other retinoids besides RA
may regulate energy metabolism in white adipose tissue. Interestingly, Raldh1 deficiency
has been shown to induce brown adipose tissue-like transcriptional program in white
adipose tissue [291]. Furthermore, retinal can induce the expression of Ucp1 mRNA and
protein in white adipose tissue by activating RAR [291]. These data show that both
retinal and RALDH1 are regulators of adaptive thermogenesis in white adipose tissue.
Thirdly, RA has distinct influences on different stages of adipocyte differentiation. In
several mouse preadipocyte cell lines and 3T3-L1 cells, RA can block the preadipocyte
differentiation through inhibiting the induction of PPARγ and CCAAT-enhancer-binding
protein α (C/EBPα) [292]. It has been shown that cellular retinoic-acid binding protein II
(CRABP II) mediates the effect of RA [293]. Interestingly, the inhibitory effect of RA on
differentiation cannot be observed in the late stage of adipocyte differentiation due to the
reduced RAR expression level [294]. Additionally, low doses of all-trans-RA potentiated
the differentiation of Ob17 mouse pre-adipocytes [295].
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9.4.2 VA and metabolism in brown adipose tissue
Brown adipose tissue, with the landmark expression of UCP1, is engaged in
thermogenesis in mammals [296]. Feeding a VAD diet in mice reduced the expression of
Ucp genes in their brown adipose tissue [297]. In contrast, retinol supplementation
induced the Ucp1 mRNA in rat brown adipocytes [211]. Additionally, in both cultured
brown adipocytes and rodent brown adipose tissue, RA treatment stimulated
thermogenesis by upregulating the expression of Ucp1 [297-299]. This regulation is
mediated through the RARE in the promoter of Ucp1 gene [300]. It has been shown that
all-trans-RA treatment also reduces the RARα and RXRα protein levels in mouse brown
adipose tissue [301]. Collectively, these data provide an interesting mechanism by which
VA and its metabolites regulate brown adipose tissue thermogenesis.
9.5 VA and metabolism in the skeletal muscle
The skeletal muscle is the largest organ in the body, which plays a critical role in the
regulation of energy metabolism [302]. However, very limited research has been
performed to investigate the effects of VA on the carbohydrate and protein metabolism in
the skeletal muscle. In avian species, VA deficiency depletes the glycogen content in the
pectoralis major muscle [303]. On the other hand, RA treatment of mouse myoblast
C2C12 cells leads to increased glucose uptake possibly through the activation of AMPactivated protein kinase [304]. In addition, VA deficiency rats have lowered protein
synthesis rate and increased proteolysis rate in the skeletal muscle [245,305]. This change
in protein metabolism partly contributes to the body mass loss in the VA deficiency
animals. Interestingly, the acute VA toxicity accelerates the myofibrillar protein
breakdown without affecting the rate of protein synthesis, which may also lead to muscle
wasting [306]. These data, though sparing, collectively demonstrate the involvement of
VA in the regulation of glucose and protein metabolism in the skeletal muscle.
In terms of the lipid metabolism, VAD rats do not show significant change in the FA
oxidation capacity in the skeletal muscle [257]. In contrast, RA treatment of mouse
skeletal muscle dose-dependently increases the transcripts of genes that are involved in
FA oxidation and thermogenesis [307]. Indeed, RA treatment and retinyl palmitate
supplementation induce the expression of UCP3 in the mouse skeletal muscle [213,288].
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Despite the different results observed between rats and mice, these data suggest that VA
may increase the energy dissipation in the skeletal muscle.

10. Conclusion
VA is a crucial regulator of carbohydrate, protein and lipid metabolism in all of the
major metabolic active organs. The manifold of the VA effects may be attributed to the
roles of RA (or other VA metabolites) in regulating the expression of critical genes in
different metabolic pathways. A lot of efforts and progresses have been made for the
understanding of the actions of VA (RA) in different organs. We think that further
investigations are warranted in the following areas: (1) the molecular mechanisms by
which VA regulates the transcription of critical metabolic genes, such as Gck, Pck1 and
Srebp-1c, in different organs and tissues; (2) the interplay between VA and other
hormones in the regulation of metabolic homeostasis; (3) the roles of VA in the
regulation of macronutrients metabolism in the disease states, especially obesity, type 2
diabetes and other metabolic diseases. The findings in the abovementioned areas will not
only help understand the effects of micronutrients on energy metabolism, but also help
create new pharmaceutical strategies to combat metabolic diseases.
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CHAPTER II. VITAMIN A AND FEEDING STATUSES
MODULATE THE INSULIN-REGULATED GENE
EXPRESSION IN PRIMARY RAT HEPATOCYTES
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Abstract
Unattended hepatic insulin resistance predisposes individuals to dyslipidemia, type 2
diabetes and many other metabolic complications. The mechanism of hepatic insulin
resistance at the gene expression level remains unrevealed. To examine the effects of
vitamin A (VA), total energy intake and feeding conditions on the insulin-regulated gene
expression in primary hepatocytes of Zucker lean (ZL) and fatty (ZF) rats, we analyze the
expression levels of hepatic model genes in response to the treatments of insulin and
retinoic acid (RA). We report that the insulin- and RA-regulated glucokinase, sterol
regulatory element-binding protein-1c and cytosolic form of phosphoenolpyruvate
carboxykinase expressions are impaired in hepatocytes of ZF rats fed chow or a VA
sufficient (VAS) diet ad libitum. The impairments are partially corrected when ZF rats
are fed a VA deficient (VAD) diet ad libitum or pair-fed a VAS diet to the intake of their
VAD counterparts in non-fasting conditions. Interestingly in the pair-fed ZL and ZF rats,
transient overeating on the last day of pair-feeding regimen changes the expression levels
of some VA catabolic genes, and impairs the insulin- and RA-regulated gene expression
in hepatocytes. These results demonstrate that VA and feeding statuses modulate the
hepatic insulin sensitivity at the gene expression level.
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1. Introduction
The liver is critical for glucose and lipid homeostasis, which is achieved partially
through the regulation of hepatic genes expression in response to hormonal and
nutritional stimuli [24,37]. The disturbance of these responses may lead to the
development of metabolic diseases, including obesity and type 2 diabetes [24]. Even
though the pathogenesis of these diseases has not been fully elucidated, insulin resistance
is established as the key risk factor [308]. Current theory postulates that overnutrition
triggers system inflammation, dysregulates lipid metabolism, and alters gastrointestinal
microbiota, all of which may interplay and lead to impaired insulin action in the body
[38].
The insulin-regulated hepatic metabolism is partially attributed to the regulation of
hepatic genes expression. For instance, in primary rat hepatocytes, insulin induces the
glucokinase (GCK, gene Gck) expression to promote glycolysis and suppresses the
phosphoenolpyruvate carboxykinase (PEPCK-C, gene Pck1) expression to reduce
gluconeogenesis [309,310]. Insulin also promotes hepatic lipogenesis via inducing sterol
regulatory element-binding protein 1c (SREBP-1c, gene Srebp-1c) expression. SREBP1c induces the expression of hepatic lipogenic genes, such as acetyl-coenzyme A
carboxylase and fatty acid synthase [311]. In insulin resistant liver, insulin is unable to
suppress the expression of gluconeogenic genes. But it is able to concurrently induce the
expression of lipogenic genes [37]. This phenomenon demonstrates the coexistence of
hyperglycemia and hyperlipidemia in the type 2 diabetic.
As an essential lipophilic micronutrient, vitamin A (VA, retinol) is implicated in the
regulation of glucose and lipid metabolism [24]. Two stepwise cytosolic enzymatic
reactions convert retinol into retinoic acid (RA, all-trans RA or 9-cis RA), which then
enters the nucleus and modules gene expression through the activation of retinoid acid
receptors and retinoid X receptors [127]. Recent reports by our group show that RA
synergizes with insulin to induce the Gck and Srebp-1c expressions in primary rat
hepatocytes [235,266]. RA attenuates the insulin-suppressed Pck1 expression in the same
cells [240]. These data suggest that micronutrient status can affect hepatic insulin
sensitivity at the gene expression level. However, the roles of caloric intake and
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micronutrient composition in the hepatic insulin resistance at the gene expression level
have not been investigated.
Here, we chose Zucker lean (ZL) and ZF rats as insulin sensitive and resistant models,
respectively, to investigate the effects of energy intake and VA status on the hepatic
insulin sensitivity at the gene expression level. We demonstrate that VA deficiency
partially corrects the impaired insulin-regulated gene expression in ZF primary
hepatocytes. More importantly, transient overeating in ZL and ZF rats causes the
impairment of insulin-regulated gene expression in their primary hepatocytes.

2. Materials and methods
2.1 Animals and rodent diets
Zucker rats (Harlan Laboratories) were bred and housed on a 12 hr light-dark cycle
under constant temperature and humidity in the animal facility at University of Tennessee
at Knoxville. Breeding pairs were kept on Teklad rodent chow (#8640, Harlan
Laboratories, Indianapolis, IN). Weaned male ZL (fa/+ or +/+) and ZF (fa/fa) rats (21
days old) were fed experimental diets for 8 weeks before primary hepatocyte isolation.
Synthetic VA sufficient (VAS, #5755, 22.1 IU/g VA) and VA deficient (VAD, #5822, 0
IU/g VA) diets were isocaloric diets from TestDiet (Richmond, VA). All procedures
(Protocol #1256, #1863) were approved by the Institutional Animal Care and Use
Committee at UTK.
2.2 Pair-feeding study.
Male ZL or ZF rats (VAD-AD group, and VAD ad libitum, 5 rats per group) had free
access to the VAD diet and water for 56 days. The body mass and food intake were
recorded every 2 days. Primary hepatocytes were isolated on Day 56. Two pair-feeding
groups were set up to circumvent a potential caveat on the last day of pair-feeding. Since
VAD animals consume significantly less diet than their VAS counterparts in ad libitum
feeding condition [206], the VAS pair-fed rats would conceivably consume the last day’s
ration rapidly. This caveat would result in a fasting status in these rats and affect the
analysis of insulin-regulated hepatic gene expression. Therefore, 10 rats with matching
genotypes were paired up with rats in VAD-AD group according to weaning body mass.
They were pair-fed the VAS diet for 55 days to the intakes of their VAD-AD
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counterparts. During the course of pair-feeding, unfinished food pellets were rolled over
to ensure that equal total calories were provided. The body mass and food intake of these
rats were recorded daily. On Day 56, one group, VAS-PF-AD (VAS pair-feeding last day
ad libitum), was allowed to have free access to the VAS diet to prevent fasting energy
status. The other group, VAS-PF-4M (VAS pair-feeding last day 4 meals), was fed the
VAS diet to the amount consumed by the VAD-AD group. One fourth of the ration was
provided to VAS-PF-4M rats every 6 hrs, so that they remained non-fasted energy status
till the end of the study. Before primary hepatocyte isolation, the tail tip whole blood
glucose was measured using a LifeScan OneTouch® Ultramini glucometer (Milpitas,
CA).
2.3 Primary hepatocyte isolation.
The primary hepatocytes were isolated according to previously described protocol
[312]. The rat was euthanized by primary carbon dioxide asphyxiation, and then
secondary cervical dislocation according to the protocol. A peristaltic pump with the flow
rate of 10ml/min was set up to infuse about 120 ml liver perfusion buffer and 120 ml
liver digestion buffer. A catheter connected to the pump was inserted into the portal vein.
The inferior vena cava was punctured to allow the outflow of blood and buffers. The liver
was then excised and put into a cell culture dish containing liver digestion buffer to
remove connective tissues. The released hepatocytes were filtered through a 100 µm cell
strainer and collected by 50×g centrifugation for 3 min. The hepatocytes were washed
twice

with

high

glucose

DMEM

containing

8%

fetal

bovine

serum,

1%

penicillin/streptomycin. Isolated hepatocytes were seeded on 60-mm collagen type I
coated dishes at 2×106 cells per dish and incubated in high glucose DMEM containing
8% fetal bovine serum, 1% penicillin/streptomycin at 37˚C and 5% CO2 for 3 hrs. The
attached hepatocytes were washed once with PBS and pretreated in medium A (Medium
199 with 100 nM dexamethasone, 100 nM 3,3’,5-triiodo-L-thyronine (T3), and 1%
penicillin/streptomycin) containing 1 nM insulin at 37˚C and 5% CO2 for 14-16 hrs.
2.4 Insulin and RA treatments, RNA extraction and real-time PCR.
The pretreated hepatocytes were washed once with PBS, and then treated for 6 hrs at
37˚C and 5% CO2 with medium A containing indicated concentrations of insulin (0 nM
to 100 nM) with or without 5 µM RA. The methods for total RNA extraction and cDNA
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synthesis were described elsewhere [313]. The gene expression level was determined by
real-time PCR with respective primer sets, and normalized to the mRNA level of
ribosomal gene 36B4. The data were presented as either minus Δ cycle threshold (Ct) or
the induction fold (ΔΔCt) for which the control treatment group was arbitrarily set as 1.
2.5 Statistical Analysis.
Statistical analyses were performed using SPSS 19.0 software. Student t-test was used
to compare the means between two treatments. One-way ANOVA with LSD post-hoc
test was used to compare the means of three or more treatments. Two-way ANOVA with
Bonferroni’s post-hoc test was used to determine the effects of diets and genotypes on
hepatic gene expression. Data were presented as means ± SEM. The number of
experiments indicates hepatocyte isolations from different animals. A p value less than
0.05 is considered statistically significant.

3. Results
3.1 The insulin- and RA-regulated Gck, Pck1, and Srebp-1c expressions were
impaired in the primary hepatocytes from ZF rats fed chow ad libitum
compared with ZL rats.
We compared the insulin-regulated gene expression in primary hepatocytes from ZL
and ZF rats fed chow ad libitum. Insulin dose-dependently induced the Gck and Srebp-1c
expressions (Figure 2-1A and C), and suppressed the Pck1 expression (Figure 2-1B) in
ZL hepatocytes. RA (5 µM) synergized with insulin to induce the Gck and Srebp-1c
expressions (Figure 2-1A and C). The elevated Pck1 level in the presence of RA was still
lowered by insulin at 1 nM or higher (Figure 2-1B). Comparably in ZF hepatocytes, the
fold inductions of Gck by insulin (marked by *) and RA + insulin (marked by #) at the
corresponding concentrations were significantly lower than that in ZL hepatocytes
(Figure 2-1A). The inductions of Srebp-1c by insulin (0.1 nM to 100 nM) and RA +
insulin (0.1 nM to 100 nM) were abolished in ZF hepatocytes (Figure 2-1C). Additionally,
the insulin-mediated suppression of Pck1 was less profound in ZF hepatocytes compared
with that in ZL hepatocytes (Figure 2-1B, marked by * and #). Furthermore, the
expressions of liver type pyruvate kinase gene (Pklr) in primary hepatocytes from either
ZL or ZF rats were not affected by insulin and RA treatments (Figure 2-1D). These data
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Figure 2-1. Impaired insulin-regulated gene expression in primary hepatocytes
isolated from ZF, but not ZL, rats fed chow ad libitum. ZL and ZF rats were fed
standard chow for eight weeks before primary hepatocytes were harvested. The primary
hepatocytes were incubated in medium A with increasing concentrations of insulin (0 nM
to 100 nM) in the absence or presence of RA (5 µM) for 6 hrs. Total RNA was extracted,
synthesized into cDNA, and then subjected to real-time PCR analysis for the expression
levels of Gck (A), Pck1 (B), Srebp-1c (C), and Pklr (D). The expression level of each
gene transcript in ZL or ZF hepatocytes treated with vehicle control was arbitrarily set to
1. The data were expressed as fold induction. All p<0.05; for (A), a’<b’<c’, a<b<c, d’<e’,
d<e; for (B), f’>g’>h’, f>g>h, i’>j’, i>k; for (C), l’<m’<n’, m<o, p’<q’, r<s using oneway ANOVA;

* or # for comparing ZL or ZF at corresponding treatments using

Student’s t-test, respectively.
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(A) Gck

(B) Pck1

Figure 2-1
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(C) Srebp-1c

(D) Pklr

Figure 2-1 Continued
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demonstrated the hepatic insulin resistance at the gene expression level in ZF rats fed
chow ad libitum.
3.2 The insulin- and RA-regulated Gck, Pck1 and Srebp-1c expressions were
partially recovered in the primary hepatocytes from ZF rats fed a VAD diet ad
libitum.
VA deficiency reduced food intake, body mass, plasma insulin and triglyceride levels
in Zucker rats [312]. Hence, it may attenuate the impairment of the insulin-regulated gene
expression in ZF rat hepatocytes. Figure 2-2A (left panel) showed that, in both VAD and
VAS ZL primary hepatocytes, insulin dose-dependently induced the Gck expression (first
and second column clusters), and RA synergized with insulin to induce its expression
(third and fourth column clusters). The fold inductions of Gck expression by insulin
(marked by *) or by RA + insulin (marked by #) in the VAS ZL hepatocytes were
significantly higher than that in VAD ZL hepatocytes at the corresponding insulin
concentrations. In comparison, the insulin-induced Gck expression was impaired in both
VAD and VAS ZF hepatocytes regardless of RA (Figure 2-2A, right panel).
Insulin dose-dependently suppressed the Pck1 expression in both VAD and VAS ZL
hepatocytes (Figure 2-2B, left panel, first and second column clusters). RA induced the
Pck1 expression. Insulin at 1 nM to 100 nM suppressed the Pck1 expression by over 90%
in both VAD and VAS ZL hepatocytes (third and fourth column clusters). The net Pck1
mRNA levels in the presence of RA were higher than that in the absence of RA. On the
other hand, the insulin-suppressed Pck1 expression was impaired in VAS ZF hepatocytes.
Insulin at 0.1 nM or 1 nM only suppressed 10% or 40% of the Pck1 expression level,
respectively. However, in VAD ZF hepatocytes, the suppression of Pck1 expression by
0.1 nM or 1 nM insulin was 40% or 60%, respectively, suggesting improved regulation
by insulin (Figure 2-2B, right panel, first and second column clusters). RA induced the
Pck1 expression in VAD and VAS ZF hepatocytes (right panel, third and fourth column
clusters). Insulin at 0.1 nM or 1 nM respectively suppressed the Pck1 expression by 50%
or 70% in VAD ZF hepatocytes, which was greater than 20% or 50% in VAS ZF
hepatocytes.
Insulin dose-dependently induced the Srebp-1c expression, and RA synergized with
insulin to induce its expression in both VAD and VAS ZL hepatocytes (Figure 2-2C, left
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Figure 2-2. The impaired insulin-regulated gene expression in primary hepatocytes
from ZF rats was partially recovered in rats fed a VAD diet for 8 weeks. ZL and ZF
rats were fed either a VAS or VAD diet for 8 weeks. Primary hepatocytes were isolated
from rats in ad libitum. Cells were incubated in medium A with increasing concentrations
of insulin (0 nM to 100 nM) in the absence or presence of RA (5 µM) for 6 hrs. Total
RNA was extracted, synthesized into cDNA, and then subjected to real-time PCR
analysis for the expression levels of Gck (A), Pck1 (B), and Srebp-1c (C). The data were
expressed as fold induction. The gene transcript levels from the no treatment group (0 nM
insulin, no RA) for both ZL and ZF were arbitrarily set to 1. All p<0.05; for (A), a<b<c,
d<e<f, g<h<i, j<k<l, m<o, p<r/s/t, q<s/t, r<t, x<y; for (B), a’>b’>c’, d’>e’>f’, g’>h’>i,
j’>k’>l’, m’>n’, o’>q’/r’, p’>r’, s’>t’>u’, v’>x’/y’, w’>y’; for (C), a”<b”<c”, d”<e”<f”,
h”<i”<j”, k”<m”, n”<p”, q”<s”, using one-way ANOVA. * or # for comparing ZL and
ZF at corresponding treatments using Student’s t-test, respectively.

!

58

(A) Gck - ZL

ZF

Figure 2-2
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(B) Pck1 - ZL

ZF

Figure 2-2 Continued

!

60

(C) Srebp-1c - ZL

ZF

Figure 2-2 Continued
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panel). The fold inductions of Srebp-1c expression by insulin (marked by *) or by insulin
and RA (marked by #) in VAS ZL hepatocytes were significantly lower than that in VAD
ZL hepatocytes. In VAS ZF hepatocytes, the insulin-induced Srebp-1c expression in the
absence or presence of RA was abolished (Figure 2-2C, right panel). Interestingly in
VAD ZF hepatocytes, insulin (1 nM to 100 nM) partially regained the ability to induce
the Srebp-1c expression, showing improved regulation (first and third cluster).
3.3 ZL or ZF rats pair-fed the VAS diet tended to overeat when sufficient amount of
diet was provided.
Rats on the VAD diet reduced food intakes at around 5 weeks after weaning [206]. To
determine how total and acute food intakes affect insulin-regulated hepatic gene
expression, an 8-week pair-feeding experiment was designed. Rats were divided into
three groups, VAD-AD, VAS-PF-AD and VAS-PF-4M (Figure 2-3A, see Materials and
Methods for detail). Figure 2-3B shows that VAS-PF-AD ZL and ZF rats ingested 54%
and 112% more food on the last day than VAD-AD ZL and ZF rats did, respectively,
demonstrating the overeating of VAS-PF-AD rats. The overeating of VAS-PF-AD rats
did not significantly increase the total caloric intake over the entire pair-feeding period
compared to VAD-AD and VAS-PF-4M counterparts (Figure 2-3C). Correspondingly,
VAS-PF-AD ZL and ZF rats gained 4% and 6% of body mass on the last day,
respectively (Figure 2-3D). Before sacrifice, the tail tip whole blood glucose levels of
VAS-PF-AD ZF rats were significantly higher than those of VAD-AD and VAS-PF-4M
rats (Figure 2-3E).
3.4 ZL and ZF rats pair-fed the VAS diet had higher body mass and feed efficiency
than their VAD fed counterparts after the reduction of food intake.
During the 56-day pair-feeding regimen, the two-day food intake of VAD-AD ZL rats
gradually increased from ~10 g initially to ~40 g on days 33-34, and kept relatively stable
until days 41-42 (Figure 2-4A, left panel). As anticipated, the food intake then started to
decline until the end of the dietary manipulation. The two-day food intake of VAD-AD
ZF rats quickly rose from ~10 g initially to ~60 g on days 17-18, leveled off between
days 20 to 34, started to decline on days 35-36, reached ~30 g on days 47-48, and leveled
off again until the end of the dietary manipulation (right panel). During the same period,
all VAS pair-fed ZL and ZF rats received the same amount of the isocaloric VAS diet to
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Figure 2-3. VAS-PF-AD ZL and ZF overate on the last day when sufficient VAS diet
was provided. (A) The schematic graph of the setup for the pair-feeding regime. VAD ad
libitum (VAD-AD, n=5), VAS pair-feeding last day ad libitum (VAS-PF-AD, n=5), VAS
pair-feeding last day 4 meals (VAS-PF-4M, n=5) (B) Tail tip whole blood glucose from
ZL and ZF rats before sacrifice. Each circle represents a value from an individual animal.
The bars represent mean ± S.E.M. * Indicates p<0.05 using one-way ANOVA with LSD
post-hoc test. (C) The accumulative food intake for ZL and ZF rats over 56 days of pairfeeding regime. (D) The food intake and (E) body mass change for ZL and ZF rats on day
56 of the pair-feeding regime. * Indicates p<0.05 using one-way ANOVA with LSD
post-hoc test.
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(C)

Figure 2-3
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(D)

(E)

Figure 2-3 Continued
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Figure 2-4. The food intake, body mass and cumulative feed efficiency over 56 days
of dietary manipulation. (A) Two-day food intake of ZL and ZF on VAD ad libitum
(VAD-AD, n=5), VAS-Pair-feeding Last Day ad libitum (VAS-PF-AD, n=5), VAS-Pairfeeding Last Day 4 meals (VAS-PF-4M, n=5) (B) Body mass of ZL and ZF on VAD AD,
VAS-PF AD and VAS-PF 4M. (C) Cumulative feed efficiency (unit weight gain per unit
diet consumed) of ZL and ZF on VAD-AD, VAS-PF-AD and VAS-PF-4M. * Indicates
p<0.05 using one-way ANOVA with LSD post-hoc test.
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match the energy intake of VAD-AD rats. The body mass of VAD-AD ZL and ZF rats
ceased to increase after 36 days of dietary manipulation (Figure 2-4B). From day 34, the
body mass of VAD-AD ZL or ZF rats was significantly lower than that of VAS-PF ZL or
ZF rats, respectively (marked by *). Furthermore, the cumulative feed efficiency of all
three groups decreased over time. However, VAS-PF ZL or ZF rats had significantly
higher feed efficiency than VAD-AD ZL or ZF rats after 36 or 22 days, respectively
(Figure 2-4C).
3.5 Transient overeating impaired the insulin-induced Gck expression in the
primary hepatocytes of VAS-PF-AD ZL and ZF rats.
In ZL hepatocytes, insulin dose-dependently induced the Gck expression (Figure 25A). Without or with RA, the fold inductions by insulin in VAS-PF-AD ZL hepatocytes
were significantly lower than that in VAD-AD hepatocytes (marked by *) and VAS-PF4M ZL hepatocytes (marked by $), suggesting an impaired insulin regulation.
Additionally, the fold inductions by insulin in VAD-AD ZL hepatocytes were lower than
that of VAS-PF-4M ZL hepatocytes without or with RA (marked by #). These results
match the data shown in Figure 2-2A and indicate that VA status of ZL rats affects the
insulin-stimulated Gck expression in their hepatocytes.
In ZF hepatocytes, insulin dose-dependently induced the Gck expression regardless of
RA (Figure 2-5B). Without RA, the fold inductions by insulin (1 and 10 nM) in VAS-PFAD ZF hepatocytes were significantly lower than that in VAS-PF-4M ZF hepatocytes
(Figure 2-5B, left panel, marked by $). With RA (Figure 2-5B, right panel), the fold
inductions by insulin in VAS-PF-AD ZF hepatocytes were significantly lower than that in
VAD-AD (0.1 nM to 100 nM, marked by *) and VAS-PF-4M (1 nM to 100 nM, marked
by $) ZF hepatocytes. These data demonstrate the impairment of the insulin-induced Gck
expression in VAS-PF-AD ZF hepatocytes.
3.6 The insulin-suppressed Pck1 expression was partially impaired in primary
hepatocytes of VAS-PF-AD ZL rats compared with VAD-AD and VAS-PF-4M
ZL rats.
In VAD-AD and VAS-PF-4M ZL hepatocytes, insulin at 0.1 nM suppressed Pck1
expression of by 60% and 70%, respectively (Figure 2-6A). The insulin-mediated
suppression reached over 90% at 1 nM to 100 nM (left panel). In VAS-PF-AD ZL
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Figure 2-5. Insulin-induced Gck expression was attenuated in hepatocytes from VAS-PF-AD, but not VAS-PF-4M rats. The
primary hepatocytes were treated by insulin (0 nM to 100 nM) with or without RA (5 µM) in medium A for 6 hrs. The expression
levels of Gck in ZL hepatocytes (A) and ZF hepatocytes (B) were determined by real-time PCR analysis, and the data were expressed
as fold inductions. The gene transcript levels from the no treatment group (0 nM insulin, no RA) for both ZL and ZF were arbitrarily
set to 1. All p<0.05; for (A), a<b<c, a’<b’<c’, a”<b”<c”, d<e<f, d’<f’/g’, e’<g’, d”< e”<f”; for (B), h<i<j, h’<i’, h”<i”<j”, k<l<m,
j’<k’<l’, k”<i”<m”, using one way ANOVA. *, #, and $ for comparing the effects of dietary manipulations at any treatment using one
way ANOVA
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Figure 2-6. Transient overfeeding of VAS diet impaired insulin-suppressed Pck1
expression in hepatocytes of VAS-PF-AD ZL, but not ZF, rats. The primary
hepatocytes were treated by insulin (0 nM to 100 nM) with or without RA (5 µM) in
medium A for 6 hrs. The expression levels of Pck1 in ZL hepatocytes (A) and ZF
hepatocytes (B) were determined by real-time PCR analysis, and the data were expressed
as fold inductions. The gene transcript levels from the no treatment group (0 nM insulin,
no RA) for both ZL and ZF were arbitrarily set to 1. All p<0.05; for (A), a>b>c, a’>c’,
a”>b”>c”, d>e>g, d>f, d’>f’/g’, e’>g’, d”>e”>f”>g”; for (B), h>i, h’>i’>j’, h”>i”>j”, k>l,
k’>l’>m’, k”>l”, using one way ANOVA. *, #, and $ for comparing the effects of dietary
manipulations at any treatment using one way ANOVA.
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hepatocytes, the Pck1 expression levels in the presence of 1 nM to 100 nM insulin were
significantly higher than that in VAD-AD and VAS-PF-4M ZL hepatocytes (marked by *
and $, respectively). In the presence of RA, insulin at 0.1 nM to 100 nM reduced the
elevated Pck1 mRNA levels in all three groups of ZL hepatocytes (Figure 2-6A, right
panel).
For ZF hepatocytes, insulin at 0.1 nM to 100 nM significantly suppressed the Pck1
expression in VAD-AD, VAS-PF-AD and VAS-PF-4M groups (Figure 2-6B, left panel).
With RA, insulin reduced the elevated Pck1 mRNA levels in VAS-PF-AD (0.1 nM to
100 nM), VAD-AD (1 nM to 100 nM) and VAS-PF-4M (1 nM to 100 nM) ZF
hepatocytes (right panel). Interestingly, the Pck1 expression levels in VAS-PF-AD ZF
hepatocytes were significantly lower than those in VAD-AD ZF hepatocytes at every
concentration (marked by *).
3.7 The insulin-induced Srebp-1c expression was impaired by transient overeating in
hepatocytes of VAS-PF-AD ZL and ZF rats.
In VAD-AD and VAS-PF-4M ZL hepatocytes, insulin at 0.1 nM to 100 nM induced
the Srebp-1c expression with or without RA (Figure 2-7A). The fold inductions of Srebp1c by insulin (1 nM to 100 nM) and insulin + RA (10 nM to 100 nM) in VAS-PF-AD ZL
hepatocytes were significantly lower than that in VAD-AD (marked by *) and VAS-PF4M ZL (marked by $) ZL hepatocytes at the corresponding treatments.
In VAD-AD and VAS-PF-4M ZF hepatocytes, insulin at 1 nM to 100 nM induced the
Srebp-1c expression with or without RA (Figure 2-7B). In contrast, the insulin-mediated
inductions of Srebp-1c expression were abolished in VAS-PF-AD ZF hepatocytes
regardless of RA. As a result, the fold inductions in VAS-PF-AD ZF hepatocytes were
significantly lower than that in VAD-AD (marked by *) and VAS-PF-4M ZF (marked by
$) hepatocytes. These data demonstrate that the transient overeating of VAS-PF-AD rats
impairs the insulin-induced Srebp-1c expression in their hepatocytes.
3.8 Dietary manipulation and VA status regulated the expression levels of genes for
VA metabolism in hepatocytes from ZL and ZF rats.
To understand the impact of transient overeating on the hepatic VA metabolism, we
analyzed the expression levels of key enzymes for VA metabolism and RA responses in
all three groups of ZL and ZF hepatocytes. As shown in Figure 2-8A, the expression level
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Figure 2-7. Transient overfeeding of VAS diet impaired insulin-induced Srebp-1c expression in hepatocytes of VAS-PF-AD ZL
and ZF rats. The primary hepatocytes were treated by insulin (0 nM to 100 nM) with or without RA (5 µM) in medium A for 6 hrs.
The expression levels of Srebp-1c in ZL hepatocytes (A) and ZF hepatocytes (B) was determined by real-time PCR analysis, and the
data was expressed as fold induction. The gene transcript levels from the no treatment group (0 nM insulin, no RA) for both ZL and
ZF were arbitrarily set to 1. All p<0.05; for (A), a<b<c<d, a’<b’, a”<b”<c”, e<f, c’<g’/f’, d’<f’, d”<e”<f”; for (B), g<h, g”<i”/j”,
h”<j”, i<k/l, j<l, h’<l’, k”<l”, using one way ANOVA. *, #, and $ for comparing the effects of dietary manipulations at any treatment
using one way ANOVA.
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Figure 2-8. Differential expression levels of indicated transcripts for vitamin A
metabolism in the primary hepatocytes of ZL and ZF rats. The expression levels of
Rbpr2 (A), Rdh2 (B), Raldh1 (C), Raldh4 (D), Cyp26a1 (E), and Rarb (F) were
determined by real-time PCR in the cultured primary hepatocytes receiving no treatment.
The data were expressed as -ΔCt (36B4-interest gene). All p<0.05; *, #, and $ for
comparing the effects of dietary manipulation variables on gene transcript levels using
two-way ANOVA with Bonferroni’s post-hoc test; a>b, and c>d, using Student’s t-test to
compare ZL with ZF with the corresponding dietary manipulation.
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of RBP4 receptor 2 (Rbpr2), a proposed liver-specific retinol transporter [111], was
higher in VAD-AD hepatocytes than that in VAS-PF-AD and VAS-PF-4M hepatocytes
(both ZL and ZF). RDH2 catalyzes the reversible conversion between retinol and
retinal[100]. In Figure 2-8B, the expression level of Rdh2 in VAD-AD ZL or ZF
hepatocytes was higher than that in VAS-PF-4M ZL or ZF hepatocytes, respectively. The
expression level of Rdh2 in VAS-PF-AD ZL hepatocytes was higher than that in VASPF-4M, but lower than that in VAD-AD ZL hepatocytes.
Both RALDH1 and RALDH4 are involved in the irreversible conversion of retinal
into RA [100]. The Raldh1 expression level in VAS-PF-AD ZL or ZF hepatocytes was
significantly lower than that in VAD-AD and VAS-PF-4M ZL or ZF hepatocytes,
respectively (Figure 2-8C). The Raldh4 expression level in VAD-AD ZL hepatocytes was
higher than that in VAS-PF-AD and VAS-PF-4M groups (Figure 2-8D), suggesting the
alteration of VA metabolism in the liver. However, the Raldh4 expression levels in all
groups of ZF hepatocytes were similar.
Additionally, the expression level of Cyp26a1 (Figure 2-8E), a RA catabolic gene
[145,313], in VAD-AD ZL hepatocytes was significantly lower than that in VAS-PF-AD,
but higher than that in VAS-PF-4M ZL hepatocytes. The Cyp26a1 expression level in
VAD-AD ZF hepatocyte was lower than that in VAS-PF-AD and VAS-PF-4M ZF groups.
The Rarb expression levels were not different among VAD-AD, VAS-PF-AD, and VASPF-4M groups (Figure 2-8F).
Two-way ANOVA analysis showed that dietary manipulations accounted for the
majority of overall variance observed in the expression levels of Rbpr2 (F=23.04, 61%
variance explained), Rdh2 (F=13.14, 47%), Raldh1 (F=23.27, 61%), and Raldh4 (F=3.56,
22%). This suggests that dietary manipulation can potentially change the availability of
RA in primary hepatocytes by changing the expression levels of VA metabolic genes.
Aside from the genes described above, we also checked Stra6, Rdh10, Raldh2 and
Raldh3, whose transcript levels in primary hepatocytes were too low to be determined by
real-time PCR analysis.
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4. Discussion
Elucidating the molecular mechanisms resulting in hepatic insulin resistance is of
great clinical importance. It helps understand the development and progression of
metabolic diseases. We investigated the effects of food intake and VA status on the
insulin-regulated gene expression in ZL and ZF primary rat hepatocytes. ZF rat, which
bears a loss-of-function leptin receptor gene, develops obesity, dyslipidemia and insulin
resistance due to hyperphagia [314]. We found that the insulin-regulated Gck, Pck1 and
Srebp-1c expressions were impaired in the primary hepatocytes of ZF rats fed chow diet
ad libitum (Figure 2-1), confirming our previous observation [312]. VA deficiency
partially corrected the impairment (Figure 2-2). We have reported that retinoids affect the
expression levels of several insulin-regulated genes in primary hepatocytes previously.
These observations are somewhat anticipated and in line with our hypothesis that both
hyperinsulinemia and RA overproduction may take part in the regulation of the
expression of genes for glucose and lipid metabolism, and contribute to hepatic insulin
resistance at the gene expression level [24].
Compared to ZL rats, ZF rats are hyperinsulinemic. Previous research showed that the
insulin binding capacity of the isolated liver plasma membrane of ZF rats was not
different from that of ZL rats [315]. In addition, the insulin-induced phosphorylation of
AKT at Ser473 and Thr308 were similar in the primary hepatocytes of ZL and ZF rats
[312]. These data indicate that the impairment of insulin-regulated gene expression in ZF
hepatocytes is likely to be caused by alterations downstream of AKT activation in the
insulin signaling cascade. Indeed, VA and insulin operate through separated pathways to
regulate hepatic gene expression. RA, as a metabolite of VA catabolism, moves to the
nucleus and activates the nuclear receptors (e.g. retinoic acid receptor, retinoid X receptor,
peroxisome proliferator-activated receptor β/δ, hepatocyte nuclear factor 4α, and chicken
ovalbumin up-stream transcription factor II) that are located in the promoters of the target
genes [24]. How these two pathways interact with each other in normal or disease states
deserves further investigation.
We also found that the degree of the impairment of Srebp-1c expression was more
profound than that of Gck and Pck1 in ZF hepatocytes (Figure 2-1). It suggests that
branching points may exist in the downstream of insulin signaling pathway, below which
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the expressions of Gck, Pck1 and Srebp-1c are differentially regulated by nutritional and
hormonal stimuli. This is in accordance with other studies. For example, a bifurcation
point at mTORC1 in the insulin signaling pathway separated the insulin-induced Srebp1c expression and the insulin-suppressed Pck1 expression [316]. The knockout of SREBP
cleaving-activating protein gene in ob/ob mice resulted in the amelioration of hepatic
lipogenesis without the improvement of hepatic gluconeogenesis [317]. Additionally in
primary rat hepatocytes treated with insulin, the Gck expression reached the peak level 6
hrs earlier than did the Srebp-1c expression [235]. Further studies are needed to dissect
these branching points and discover any change of regulation in insulin resistance.
The negative effects of the short-term overfeeding on the hepatic insulin sensitivity
have been observed in both rodents and humans. However, the underlying mechanisms
are not revealed. The pair-feeding study indicates that the transient overeating of the VAS
diet (VAS-PF-AD groups) caused the impairment of insulin-regulated Gck, Pck1 and
Srebp-1c expressions in the primary hepatocytes of ZL and ZF rats compared (Figure 2-5,
2-6, 2-7). In contrast, VAS-PF-4M ZL rats showed normal insulin-regulated gene
expression. This suggests that, in the livers of so called insulin-sensitive ZL rats, insulin
sensitivity at gene expression level can be acutely impaired after excessive food intake,
and then restored overtime. Indeed, in young human subjects, a 7-day overfeeding
increased circulating adiponectin and glucagon-like peptide 1 levels, which are proposed
to act against the hepatic insulin resistance [321,322]. On the other hand, transient
overeating of the VAS diet caused worsened impairment of insulin-regulated Gck and
Srebp-1c expressions in the primary hepatocytes of ZF rats (Figure 2-5, 2-7). ZF rats
persist in overeating state due to deficient leptin signaling. This may hamper the
restoration of insulin sensitivity after food intake. As a result, ZF rats fed VAS or chow
ad libitum manifest the hepatic insulin resistance at the gene expression level.
Long term VA deficiency decreased the insulin-regulated expression of Gck, but not
Pck1 and Srebp-1c. In VAS-PF-AD ZL rats, the insulin-induced Gck expression was
significantly lower than that in VAS-PF-4M ZL rats (Figure 2-5), showing that adequate
VA status is instrumental to the insulin-regulated Gck expression in insulin-sensitive ZL
primary hepatocytes. This observation demonstrates that VA status differentially affects
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the hepatic insulin-regulated gene expression, suggesting complex interactions of VA and
insulin signaling systems.
The impairment of insulin-induced Gck (Figure 2-5) and insulin-suppressed Pck1
expressions (Figure 2-6) in VAS-PF-AD hepatocytes suggests an elevation of plasma
glucose level and an acute loss of insulin-sensitivity in over-eating state. This is
supported by the elevated tail tip whole blood glucose level observed in these animals
(Figure 2-3E), and may explain the elevated hepatic glucose production in human
subjects who are overfed for short terms [318,319]. The dysregulation of insulin-induced
hepatic Srebp-1c expression after the transient overeating (Figure 2-7) suggests increased
de novo lipogenesis, which may explain the increased hepatic fat content observed in
short-term overfed humans [320]. More importantly, the impairment was observed in
both ZL and ZF rats after transient overeating. These data suggest the existence of a
mechanism that may dynamically regulate hepatic insulin sensitivity at the gene
expression level in response to feeding status.
Short-term overeating provides excessive intake of not only calories but also
micronutrients. We showed transient overeating for one day greatly affected the
expression levels of genes involved in VA metabolism in the ZL and ZF rat hepatocytes
(Figure 2-8). VAD-AD rats exhibited high hepatic levels of Rbpr2, Rdh2, Raldh1 and
Raldh4 transcripts, showing compensatory upregulation of the VA metabolic genes. In
contrast, VAS-PF-4M rats exhibited low hepatic transcript levels of Rbpr2, Rdh2 and
Raldh4. These suggest that the hepatic VA metabolic gene expression is greatly
influenced by the availability of dietary VA.
VAS-PF-AD rats had lowered hepatic levels of Rbpr2 and Raldh1 transcripts. Indeed,
the Rbpr2 expression is inversely related to the liver retinol stores, and RA reduces the
Rbpr2 mRNA level in HepG2 cells [111]. Additionally, the elevated RA controls its
biosynthesis by down-regulating RALDH1 through the modulation of retinoic acid
receptor α and CCAAT/enhancer binding protein β [138,139].These suggest that the
expression levels of VA metabolic genes are modulated in VAS-PF-AD rats to prevent
the RA overproduction in response to the transient influx of the dietary VA. Despite the
negative feedback regulation, excessive RA may have been produced. This is supported
by the increased expression level of Cyp26a1 [145], a RA-responsive gene, in VAS-PF-
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AD hepatocytes (Figure 2-8E). The excessive RA may affect the expression of hepatic
metabolic genes, and promote the hepatic insulin resistance at the gene expression level
[24]. It is interesting to note that the VA status does not seem to affect the expression
levels of Raldh1 gene in primary hepatocytes as its expression levels are similar in VADAD and VAS-PF-4M groups. The underlying mechanism deserves further investigation.
In summary, we have demonstrated that both VA and feeding statuses affected the
hepatic insulin sensitivity at the gene expression level. This finding provides insight into
the development of the hepatic insulin resistance, and helps find solutions to combat
metabolic diseases.
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CHAPTER III. OVEREXPRESSION OF ATYPICAL
PROTEIN KINASE Cζ (PKCζ) OR ι/λ (PKCι/λ)
ATTENUATES INSULIN-REGULATED GENE
EXPRESSION IN PRIMARY RAT HEPATOCYTES
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Abstract
Results demonstrated in the previous chapter and publications from our lab have shown
that the insulin-regulated gene expression is impaired in primary hepatocytes from
Zucker fatty (ZF), but not Zucker lean (ZL) rats fed ad libitum. We have systemically
compared the hepatic expression levels and activation statuses of the critical components
in signaling pathway between ZL and ZF rats. The preliminary data indicate that the
expression levels of atypical protein kinase Cζ (PKCζ), member of PKC family, are
higher in hepatocytes and liver of ZF than that of ZL rats. In individuals with type 2
diabetes, hepatic aPKC levels are elevated. It is postulated that increased activation of
aPKC are associated with dysregulated glucose and lipid metabolism. aPKC inhibitors
can partially correct the increased levels of hepatic lipogenic and gluconeogenic enzymes
in rodent and human hepatocytes. In order to investigate the roles of aPKC in the
impairment of the insulin-regulated gene expression, PKCζ and PKCι/λ were
overexpressed in primary hepatocytes from ZL rats using recombinant adenoviruses. The
insulin-regulated expressions of these genes were attenuated upon overexpression of
PKCζ or PKCι/λ. Interestingly, PKCζ or PKCι/λ overexpression increased the basal
transcript levels of glucokinase, sterol regulatory element-binding protein-1c and
cytosolic form of phosphoenolpyruvate carboxykinase. PKCζ and PKCι/λ overexpression
in primary hepatocytes from ZL rats significantly reduces the protein level of insulin
receptor substrate 1 (IRS1), and the phosphorylation of protein kinase B (PKB/AKT) at
Ser473, Thr308, and Thr450 in response to insulin treatment. These data demonstrate the
effects of PKCζ and PKCι/λ on the regulation of insulin signal transduction, and their
critical roles in the regulation of the insulin-regulated expressions of genes for glucose
and lipid metabolism in hepatocytes.

!

83

1. Introduction
The liver is a crucial organ for the maintenance of whole body glucose and lipid
homeostasis. Normal physiological responses to the anabolic hormone insulin stimulation
result in increased glycolysis, decreased gluconeogenesis and increased lipogenesis in the
liver [309,310]. In individuals with obesity or type 2 diabetes, normal amount of insulin
is unable to suppress hepatic glucose production, but able to promote hepatic lipid
synthesis [37]. The paradoxical coexistence of elevated gluconeogenesis and lipogenesis
in the liver is a characteristic of hepatic insulin resistance, which exacerbates
hyperinsulinemia and contributes to systemic insulin resistance [37,38]. This abnormality
will create a vicious cycle and eventually lead to the onset of overt diabetes. At present,
the knowledge about the molecular mechanisms underlying hepatic insulin resistance is
limited. The elucidation of these mechanisms will help understand the pathogenesis of an
array of metabolic diseases, including obesity, cardiovascular disease, type 2 diabetes and
non-alcoholic fatty liver disease.
In hepatic parenchymal cells, insulin initiates its signaling cascade upon binding to its
receptor on the cell membrane, which is followed by the activation of insulin receptor
substrates (IRSs) [10]. Tyrosine phosphorylation of IRS1/2 leads to the association and
activation of the phosphatidylinositol 3-kinase (PI3K). PI3K catalyzes the conversion of
phosphatidylinositol-4,5-bisphosphate into phosphatidylinositol-3,4,5-triphosphate. The
latter is a lipid messenger that anchors the downstream effector proteins, e.g.
phosphoinositide dependent protein kinase-1, protein kinase B (PKB, also known as
AKT) and atypical protein kinase C (aPKC), to the cell membrane [10]. The activations
of AKT and aPKC differentially regulate the transcription of hepatic genes for glucose
and lipid metabolism [25,32,323]. For example, insulin induces the expression of
glucokinase (GCK, gene Gck) to promote glycolysis, and suppresses the expression of
cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK, gene Pck1) to reduce
gluconeogenesis in association with the activation of AKT [25,324]. On the other hand,
the induction of sterol-responsive element binding protein 1c (SREBP-1c, gene Srebp-1c)
by insulin to promote lipogenesis is mediated not only by the activation of AKT [324],
but also by the activation of aPKC [30,33].
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Members of PKC family include classical PKC, novel PKC, and aPKC. Unlike the
other two types of PKC, aPKC does not require diacylglycerol or Ca2+ for activation.
PKCζ and PKCι/λ (genes Prkcz and Prkci) are two current members of aPKC. PKCζ
shares 70% homology in amino acid sequence with PKCι/λ (PKCι in human; PKCλ in
mouse) [25]. The tissue expression profiles of PKCζ and PKCι/λ depend on the species.
In rat muscle and adipocytes, PKCζ is more abundant than PKCι/λ. Comparably in
human muscle, adipocytes and liver, PKCι is the predominant isoform [25]. Both PKCζ
and PKCι/λ mediate a variety of physiological events, such as cell polarity establishment,
cell motility, immune response and metabolism [20,25].
Activations of PKCζ or PKCι/λ have been associated with increased lipogenesis and
insulin resistance in multiple tissues and organs [25,325]. Currently in the mouse liver,
the activation of aPKC isoforms seems to play a role in the Srebp-1c transcription and
lipogenesis. For example, in liver-specific PKCλ knockout mice, the basal transcript level
of hepatic Srebp-1c, but not Gck or Pck1, declined by 50% [30]. In a mouse model within
which the regulatory subunit of PI3K was ablated in the liver, decreased PKCζ/λ activity
was observed in association with the reduction of Srebp-1c expression [32]. On the other
hand, the insulin-induced activation of aPKC and subsequent Srebp-1c expression were
retained in the liver of diabetic mice [31,34]. PKCζ/λ is also activated in the livers of
mice on a high fat diet, which increased the expression of hepatic Srebp-1c [33]. This
effect could be negated by the overexpression of kinase-inactive form PKCζ [33].
In the hepatocytes isolated from type 2 diabetic individuals, the activation of PKCι
was elevated at the basal level and after insulin treatment [35,36]. Treatment of these
hepatocytes with PKCι inhibitors lowered the levels of lipogenic, proinflammatory and
gluconeogenic enzymes [35,36]. Moreover, metformin treatment was shown to induce
aPKC activities, and increase lipogenic and gluconeogenic enzyme levels in non-obese
human hepatocytes [326]. These data collectively suggest that aPKC isoforms are
important players in the pathogenesis of obesity and type 2 diabetes. However, the
molecular mechanisms by which aPKC activations or expressions impact insulinregulated gene expression in the liver are still unclear.
Zucker fatty (ZF) rat is a genetic model of obesity, hypertriglyceridemia and hepatic
insulin resistance [327]. We previously showed that primary hepatocytes from ZF rats fed
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chow ad libitum exhibited impairment of the insulin-regulated gene expression [312].
Interestingly, the induced-phosphorylation of AKT at Ser473 and Thr 308 in ZF rat
primary hepatocytes was not significantly different from that in Zucker lean (ZL) rat
primary hepatocytes [312]. In this study, we observed the differential expression levels of
PKCζ in the livers of ZF and ZL rats, and investigated the roles of PKCζ and PKCι/λ in
the insulin-regulated gene expression in primary rat hepatocytes. We demonstrated that
overexpression of PKCζ and PKCι/λ in ZL primary hepatocytes impaired the insulinregulated gene expression.

2. Materials and methods
2.1 Reagents
The reagents for primary hepatocyte isolation and culture including Medium 199
(#11150059), Dulbecco’s Modification of Eagle Medium (DMEM, #11995065), liver
perfusion buffer (#17701038) and liver digest buffer (#17703034) were obtained from
Invitrogen (Carlsbad, CA). RNA STAT-60 was purchased from TEL-TEST
(Friendswood, TX). Restriction enzymes were from New England BioLabs (Ipswich,
MA). The reagents for cDNA synthesis and real-time PCR were obtained from Applied
Biosystems (Foster city, CA). All real-time PCR primer sets were synthesized by SigmaAldrich (St. Louis, MO). Antibodies against β-actin (#4967), PKCζ (#9368), PKCι
(#2998), p-PKCζ/λ Thr410/403 (#9378), AKT (#9272), p-AKT Ser473 (#9271), p-AKT
Thr308 (#9275), p-AKT Thr450 (#9267), IRS1 (#2382), FAS (#3189), ACC (#3662), pACC Ser79 (#3661) used in this study were purchased from Cell Signaling Technology
(Danvers, MA). All other reagents and materials were purchased from Fisher Scientific
(Pittsburgh, PA) unless described otherwise.
2.2 Animals and diets
Zucker rats were bred and housed under constant temperature and humidity in the
animal facility at the University of Tennessee at Knoxville on a 12-hr light-dark cycle.
Male lean (ZL, fa/+ or +/+) or fatty (ZF, fa/fa) rats at weaning (3 weeks old) were kept on
Teklad rodent chow (#8640, Harlan Laboratories, Indianapolis, IN) for 8 weeks before
liver tissue collection and primary hepatocyte isolation. All procedures were approved by
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the Institutional Animal Care and Use Committee at the University of Tennessee at
Knoxville (Protocols #1256, 1642 and 1863).
2.3 Liver tissue collection, total protein preparation and total RNA extraction
The rat was euthanized by primary carbon dioxide asphyxiation, and then secondary
cervical dislocation according to regulations. A 10 ml syringe with a 21G × 1½"
hypodermic needle was used to drain blood from the liver via the inferior vena cava. The
liver was excised, sliced, snap-frozen in liquid nitrogen, and stored at -80˚C before
further analysis. A small portion of the liver tissue was homogenized in 10 volumes of
cold whole-cell lysis buffer (1% Triton X-100, 10% glycerol, 1% IGEPAL CA-630, 50
mM Hepes, 100 mM NaF, 10 mM EDTA, 1 mM sodium molybdate, 1 mM sodium βglycerophsphate, 5 mM sodium orthovanadate, 1.9 mg/ml aprotinin, 5 mg/ml leupeptin, 1
mM benzamide, 2.5 mM PMSF, pH 8.0) for 1 min. The homogenized tissue suspension
was centrifuged at 16,873×g (Eppendorf 5418 desktop centrifuge, FA-45-18-11 rotor at
14,000×rpm) and 4˚C for 20 min to remove insoluble matters. The protein concentration
of the supernatant was determined with PIERCE BCA protein assay kit (Rockford, IL).
For liver tissue total RNA extraction, a small portion of the liver tissue was homogenized
in 10 volumes of cold STAT-60 for 1 min. Total RNA was extracted according to the
instructions of the manufacturer.
2.4 Cultures of primary hepatocytes and 293 HEK cells
The primary hepatocytes were isolated according to previously described protocol
[265]. After the euthanasia of the rat, a catheter connected to a peristaltic pump was
inserted into the portal vein. The pump was set up to infuse 120 ml liver perfusion buffer
and 120 ml liver digestion buffer at the flow rate of 10 ml/min. The inferior vena cava
was punctured to allow the outflow of blood and buffers. After digestion, the liver was
then excised and put into a cell culture dish containing liver digestion buffer to remove
connective tissues and allow further digestion. The released hepatocytes were filtered
through a 100 µm cell strainer and collected by 50×g centrifugation for 3 min. The
hepatocytes were washed twice with DMEM containing 4.5 g/L glucose, 8% fetal bovine
serum, 1% penicillin/streptomycin. Isolated hepatocytes were seeded on 60-mm collagen
type I coated dishes at 2×106 cells per dish and incubated in the same medium at 37˚C
and 5% CO2 for at least 3 hrs to allow cell attachment. The attached primary hepatocytes
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were washed once with PBS and pretreated in medium A (Medium 199 with 100 nM
dexamethasone, 100 nM 3,3’,5-triiodo-L-thyronine (T3), 1 nM insulin, and 1%
penicillin/streptomycin) at 37˚C and 5% CO2 for 16-18 hrs.
HEK 293 cells were seeded and kept in DMEM containing 4.5 g/L glucose, 4% fetal
bovine serum, 1% penicillin/streptomycin at 37˚C and 5% CO2.
2.5 Cloning of the rat Prkci cDNA and subcloning of the rat Prkcz cDNA.
Based upon the rat Prkci mRNA sequence (GenBank: EU517502.1), sense 5’-ATC
CCC TCA GCC TCC AGC GG-3’ and antisense 5’-ACT GTG ACC GGG CTA ACG
GT-3’ primers were designed using Primer-BLAST tools from the National Center
Biotechnology Information. For cloning of the complete coding sequence of rat Prkci
cDNA, PCR was carried out using cDNA derived from total RNA of ZL primary
hepatocyte as the template. For subcloning of rat Prkcz, pEYFP-N1 vector containing its
complete coding sequence was generously provided by Dr. Ralf Kubitz of HeinrichHeine-Universität. The vector was used as the template for the PCR amplification of
Prkcz using sense primer 5’-ACC TCG AGA TGC CCA GCA GGA CCG AC-3’ and
antisense primer 5’- GTG AAT TCA CAC GGA CTC CTC AGC AGA C-3’. The
amplicons containing the complete coding sequences of Prkci and Prkcz cDNA
®

®

sequences were ligated into pCR 2.1 vector through TA Cloning

Kit (Invitrogen)

according to the manufacture’s protocol. The cloned Prkci and subcloned Prkcz cDNA
sequences were verified by DNA sequencing.
2.6 Generation of Ad-Prkcz and Ad-Prkci recombinant adenoviruses
®

pCR 2.1-Prkcz and pACCMV5 were digested by EcoRI to generate the insert
containing complete coding sequence of Prkcz cDNA and EcoRI-cut pACCMV5 vector,
®

respectively. pCR 2.1-Prkci and pACCMV5 were digested by HindIII/XbaI to generate
the insert containing complete coding sequence of Prkci cDNA and HindIII/XbaI doublecut pACCMV5 vector, respectively. Desired fragments were separated in 0.9% agarose
gels and purified using QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA). The
inserts containing the complete coding sequences of Prkcz and Prkci were ligated into
their corresponding pACCMV5 vectors to make pACCMV5-Prkcz and pACCMV5-Prkci
respectively. To generate Ad-Prkcz and Ad-Prkci recombinant adenoviruses, pACCMV5
!

88

plasmid containing the complete coding sequence of atypical Prkc sequences (0.8µg
each) was co-transfected with JM17 (0.2µg) into HEK293 cells in 35mm plate using
®

FuGENE 6 Transfection Reagent (Roche Applied Science, Indianapolis, IN) at 3:1 or
6:1 ratio (reagent: DNA). Transfected HEK293 cells were incubated in DMEM
containing 2% FBS at 37˚C and 5% CO2 until the formation of the viral plaques. The
crude lysate was collected and stored at -80˚C.
100µl crude lysate of Ad-Prkcz and Ad-Prkci recombinant adenoviruses were
incubated in boiling water for 10 min, and subsequently treated with proteinase K at 56˚C
for 30 min. The total viral genome was isolated from the crude lysate by phenol
chloroform extraction and dissolved in 50µl water. The presence of atypical Prkc
sequences in the viral DNA was then confirmed by PCR using specific primers.
2.7 Generation and purification of recombinant adenoviruses
HEK 293 cells were cultured in 100mm tissue culture plates until 80% confluence in
DMEM containing 4.5 g/L glucose, 2% FBS at 37˚C and 5% CO2. Ad-Prkcz and AdPrkci recombinant adenoviral crude lysates were added into the medium respectively
(lysate:medium ratio 1 to 10). The infected cells were incubated at 37˚C and 5% CO2 for
48 to 72 hrs to allow maximal cell lysis to occur. Crude lysates from 10 culture plates
were collected and combined for each recombinant adenovirus purification. NP-40 was
added into the crude lysate to reach the final concentration of 0.5% v/v. The mixture was
shaken gently at room temperature for 30 min and centrifuged at 6,000×g and 4˚C for 15
min to remove cell debris. The supernatant was transferred to a clean bottle, and 0.5 ×
volume of 20% PEG8000/2.5 M NaCl was added. The mixture was gently shaken at 4˚C
overnight, and subsequently centrifuged at 15,000×g and 4˚C for 15 min. The
precipitated pellet was re-suspended in 2–3 ml PBS. The re-suspension was spun at
6,000×g and 4˚C for 10 min to remove insoluble matter. The supernatant was transferred
into a clean tube, and CsCl was added to reach a final density of 1.34 g/ml. The mixture
was spun at 437,004×g (Beckman Optima Max-XP Ultracentrifuge, TLA 100.3 rotor at
90,000×rpm) and 25˚C for 4 hrs. The pure viral particles was collected and desalted with
the PD-10 column SephadexTM G-25M (Amersham Pharmacia Biotech AB, Sweden).
Desalted viral particle suspension was supplemented with 0.2% w/v bovine serum
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albumin and 10% v/v glycerol. The optical density (OD) at 260 nm of the suspension was
®

determined by Spectronic

GENESYSTM 5 Spectrophotometer (Thermo Scientific) to

estimate the plaque forming units (pfu) of the purified recombinant adenoviruses. We
used that 1 OD equals to 1 × 1012 pfu/ml. The purified virus was frozen and stored at 80˚C until being used.
2.8 Infection of recombinant adenoviruses and treatments of primary hepatocytes
The attached primary hepatocytes were washed once with PBS and pretreated in
medium A for pretreatment. In experiments using recombinant adenoviruses, purified
Ad-Prkcz and Ad-Prkci were also added in the medium A to allow the overexpression of
PKCζ and PKCι/λ in the primary rat hepatocytes during the pretreatment period,
respectively. The pretreated hepatocytes were then washed once with PBS, and treated
with medium A containing indicated concentrations of insulin (0 nM to 100 nM) for 6 hrs
before total RNA extraction, or for 15 min before whole cell lysate preparation.
2.9 RNA extraction and real-time PCR analysis.
The methods for total RNA extraction and cDNA synthesis were described elsewhere
[312]. In essence, total RNA was extracted from the treated hepatocytes with RNA
STAT-60 according to the manufacture’s protocol. The contaminated DNA in RNA
samples was removed using the DNA-freeTM kit. First strand cDNA was synthesized
from 2µg total RNA by cDNA synthesis kit. The gene expression level was determined
by real-time PCR with respective primer sets, and normalized to the mRNA level of
ribosomal gene 36B4. The data were presented as either minus Δ cycle threshold (Ct) or
the induction fold (ΔΔCt) for which the control treatment group was arbitrarily set as 1.
2.10

Whole cell lysate preparation

Treated primary hepatocytes were placed on ice and washed once with ice-cold
proteinase inhibitors supplemented PBS (100 mM NaF, 1 mM sodium molybdate, 1 mM
sodium b-glycerophsphate, 5 mM sodium orthovanadate, 1.9 mg/ml aprotinin, 5 mg/ml
leupeptin, 1 mM benzamide, and 2.5 mM PMSF). The cells were lysed in 400µl ice cold
whole-cell lysis buffer with proteinase inhibitors, and subsequently scraped into clean 1.5
ml centrifugation tubes. The lysates were vigorously vortexed and placed on ice for at
least 20 min. Insoluble matter was removed by centrifugation at 16,873×g and 4˚C for 20
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min. The protein concentration in the supernatant was determined with PIERCE BCA
protein assay kit.
2.11

Immunoblot analysis of protein

Proteins samples (40µg) in the whole cell lysates of primary hepatocytes or liver
tissues were separated by 8% sodium dodecyl sulfate polyacrylamide gel, and then
transferred to BIO-RAD Immuno-Blot PVDF membrane (Hercules, CA). Membranes
were blocked by incubation in a solution of 8% non-fat milk in TBST for 1h at room
temperature, and then probed with specific antibodies diluted 1/1000 in 5% BSA in
TBST overnight at 4˚C. After three times of 5 min gentle wash with TBST, membranes
were incubated with goat anti-rabbit IgG conjugated with horseradish peroxidase (1/5000
dilution in 8% non-fat milk in TBST) for 1 hr at room temperature. After three times of 5
min gentle wash with TBST, detection of antigen-bound antibody was carried out using
chemiluminescence (ECL Western Blotting Substrate, Thermo Scientific), and
subsequently exposure to X-ray films (Phenix Research Products, Candler, NC). The
films were scanned at 300dpi using a HP ScanJet 2200 Scanner. The images were stored
for the analysis of densitometry using ImageJ software (National Institute of Health, MD).
Densitometry data for each protein was normalized to β-actin levels in each sample.
2.12

Statistical Analysis.

Statistical analyses were performed using SPSS 19.0 software. Student t-test was used
to compare the means between two treatments. One-way ANOVA with LSD post-hoc
test was used to compare the means of three or more treatments. Two-way ANOVA with
Bonferroni’s post-hoc test was used to determine the effects of insulin treatments and
genotypes on hepatic gene expression. Data were presented as means ± S.E.M. The
number of experiments indicates hepatocyte isolations from different animals. A p value
less than 0.05 is considered statistically significant.

3. Result
3.1 PKCζ expression was elevated in the liver of ZF rats compared with ZL rats.
To understand the underlying signaling mechanism for the hepatic insulin resistance
at gene expression level in the liver of ZF rats, we analyzed the expression levels and
activation status of critical components in the insulin signaling pathways. Despite the
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well-reported hepatic insulin resistance, ZF rats had higher phosphorylation of AKT at
Ser473 and Thr450 in liver tissues than ZL rats (Figure 3-1A). However, the
phosphorylation of AKT at Thr308 could not be detected in the current experimental
condition. This observation shows that the insulin-induced AKT phosphorylation in ZF
rat liver tissue is unimpaired, indicating the consequences of hyperinsulinemia. In
addition, ZF rat liver showed higher protein level of FAS, which is an indicator of
increased hepatic lipogenesis (Figure 3-1A).
In ZF liver tissue, the protein level of PKCζ, but not PKCι/λ, were elevated compared
to that in ZL liver tissue (Figure 3-1). Interestingly, the level of phospho-PKCζ/λ
Thr410/403, which indicated the phosphorylation of both PKCζ, and PKC ι/λ, were
similar between ZL and ZF rat liver tissues (Figure 3-1A). The mRNA level of Prkcz, but
not that of Prkci, was also elevated in the ZF liver (Figure 3-1B). These data collectively
suggest that aPKCs seem to be involved in the development of hepatic insulin resistance
in the ZF liver.
3.2 Acute insulin treatment did not alter protein levels of total and phospho-aPKCs
in primary rat hepatocytes.
To investigate whether insulin treatment changes total and phosphorylation states of AKT
and aPKC protein levels, we examined the immunoblot of whole-cell lysates from ZL
and ZF primary hepatocytes treated by insulin (0-100 nM) for 15 min. As expected, the
protein levels of FAS, ACC and phospho-ACC Ser79 were substantially increased in ZF
hepatocytes irrespective of insulin treatments (Figure 3-2). This result indicates that the
increased hepatic lipogenic capability remains in the cultured primary hepatocytes
isolated from ZF rats more than 20 hrs ago. Insulin treatment dose-dependently induced
the phosphorylation of AKT at Ser473 and Thr308 in ZL and ZF primary hepatocytes,
but no significant difference between ZL and ZF were observed in the phosphorylation of
both sites (Figure 3-2). In contrast, the phosphorylation of AKT at Thr450 in ZL and ZF
hepatocytes was insulin-independent. The level of phospho-AKT at Thr450 was higher in
ZF hepatocytes than in ZL hepatocytes (Figure 3-2). These data suggest that the insulininduced AKT phosphorylation is not impaired in ZF rat hepatocytes. The impaired
insulin-regulated gene expression in ZF hepatocytes may be caused by other components
in insulin signaling pathway. On the other hand, insulin treatment for 15 min did not
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Figure 3-1: ZF rats on chow ad lib had elevated expression levels of PKCζ mRNA
and protein in the liver. ZL (n=4) and ZF (n=4) rats were kept on chow ad lib for 8
weeks before sacrifice. Total proteins were obtained from the liver tissues of these rats,
and subjected to immunoblot analysis. Total mRNA was extracted from the liver tissues,
synthesized into cDNA, and then subjected to real time PCR analysis. (A) Immunoblot
analysis of total liver proteins of ZL and ZF rats. (B) The mRNA levels of Prkcz and
Prcki in the livers of ZL and ZF rats. The data were presented as minus Δ cycle threshold
(Ct). * indicates p<0.05 for comparing ZL and ZF using Student’s t-test.
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Figure 3-2: Acute insulin treatment did not alter protein levels of total and phosphoaPKCs in primary rat hepatocytes. ZL and ZF rats were fed standard chow for eight
weeks before primary hepatocytes were harvested. The primary hepatocytes were
incubated in fresh medium A with increasing concentrations of insulin (0 nM to 100 nM)
for 15 min after pretreatment. Control primary hepatocytes (indicated by C) were not
replenished with fresh medium A after pretreatment. The whole cell lysates of these
hepatocytes were obtained and subjected to immunoblot analysis with antibodies
indicated in the figure (A). The figure shows the representative result of three parallel
experiments obtained from three sets of animals. (B) Densitometry analyses of the
immunoblot results. Data are arbitrary intensity units expressed as mean ± SEM. All
p<0.05; a<b, a’<b’<c’, d<e, d’<e’ using one way ANOVA. * for comparing the
difference between ZL and ZF using two way ANOVA.
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Figure 3-2 Continued
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significantly induce or suppress the protein levels of PKCζ and PKCι/λ and the
phosphorylation of PKCζ/λ at Thr410/403 in ZL and ZF primary hepatocytes (Figure 32). There was a slight induction of the total PKCζ when fresh M199 was added. However,
ZF primary hepatocytes had higher level of PKCζ than ZL primary hepatocytes (Figure
3-2), which was in line with the finding from rat liver tissues (Figure 3-1).
3.3 Overexpression of PKCζ and PKCι/λ in ZL primary hepatocytes.
To investigate whether elevated aPKC protein levels contribute to hepatic insulin
resistance, we infected ZL primary rat hepatocytes with recombinant adenoviruses AdPrkcz or Ad-Prkci, respectively. Compared to hepatocytes infected with Ad-β-gal, AdPrkcz infected hepatocytes had ~2000 fold overexpression of Prkcz mRNA, and Ad-Prkci
infected hepatocytes had ~250 fold overexpression of Prkci mRNA (Figure 3-3A and B,
*). Interestingly in the hepatocytes overexpressing PKCι/λ, 0.1-100 nM insulin
treatments significantly suppressed the expression of Prkcz by 40-60% (Figure 3-3A). On
the other hand, in the hepatocytes overexpressing PKCζ, the expression levels of Prkci at
1-100 nM insulin treatments were significantly lower than that at the corresponding
treatments in hepatocytes overexpressing β-GAL (Figure 3-3B, #).
The immunoblot of total cell lysate from Ad-Prkcz infected primary rat hepatocytes
showed ~9.3 fold overexpression of PKCζ, but not PKCι/λ, compared to Ad-β-gal
infected cells (Figure 3-4). Overexpression of PKCζ did not lead to significant increase in
phospho-PKCζ/λ Thr410/403 level. The immunoblot of total cell lysate from Ad-Prkci
infected primary rat hepatocytes manifested ~4.0 fold overexpression of PKCι/λ and
increased phosphorylation of PKCζ/λ at Thr410/403, compared to Ad-β-gal infected cells
(Figure 3-5).
3.4 Overexpression of PKCζ and PKCι/λ attenuated the insulin signaling cascade in
ZL primary rat hepatocytes.
Compared to Ad-β-gal infected primary hepatocytes, Ad-Prkcz infected hepatocytes
showed similar level of total AKT, but the insulin-induced phosphorylation of AKT at
Ser473 and Thr308, and insulin-independent phosphorylation of AKT at Thr450 were
attenuated in these cells (Figure 3-4). Ad-Prkcz infected hepatocytes also had lower
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Figure 3-3: Overexpression of PKCζ and PKCι/λ attenuated the insulin signaling
cascade in ZL primary rat hepatocytes. ZL rats were fed standard chow for eight
weeks before primary hepatocytes were harvested. Purified Ad-Prkcz and Ad-Prkci were
added in the medium A during the pretreatment period to allow the overexpression of
PKCζ and PKCι/λ. Purified Ad-β-gal was used as a control recombinant adenovirus. The
primary hepatocytes were then incubated in fresh medium A with increasing
concentrations of insulin (0 nM to 100 nM) for 6 hrs before total RNA extraction Total
mRNA was extracted, synthesized into cDNA, and then subjected to real time PCR
analysis. The data were expressed as fold induction. The gene transcript levels from Adβ-gal infected primary hepatocytes with 0 nM insulin treatment were arbitrarily set to 1.
(A) The mRNA levels of Prkcz in the ZL primary hepatocytes (n=4) overexpressing βGAL, PKCζ and PKCι/λ in response to insulin gradient treatments. All p<0.05; a>b
using one way ANOVA. * for comparing fold inductions at corresponding treatments
using one way ANOVA. (B) The mRNA levels of Prkci in the ZL primary hepatocytes
(n=4) overexpressing β-GAL, PKCζ and PKCι/λ in response to insulin gradient
treatments. All p<0.05; * and # for comparing fold inductions at corresponding
treatments using one way ANOVA.
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Figure 3-4: Overexpression of PKCζ attenuated the insulin signaling cascade in ZL
primary rat hepatocytes. ZL rats were fed standard chow for eight weeks before
primary hepatocytes were harvested. Purified Ad-Prkcz was added in the medium A
during the pretreatment period to allow the overexpression of PKCζ. Purified Ad-β-gal
was used as a control recombinant adenovirus. The primary hepatocytes were then
incubated in fresh medium A with increasing concentrations of insulin (0 nM to 100 nM)
for 15 min before whole cell lysate preparation. The whole cell lysates were subjected to
immunoblot analysis with antibodies indicated in the figure. The figure shows the
representative result of three parallel experiments obtained from three sets of animals.
(A) Immunoblot analysis of Ad-Prkcz infected ZL primary hepatocytes treated with
increasing concentrations of insulin for 15 min. (B) Densitometry analyses of the
immunoblot results. Data are arbitrary intensity units expressed as mean ± SEM. All
p<0.05; a<b, c<d<e using one way ANOVA. * for comparing the difference between ZL
and ZF using two way ANOVA.
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Figure 3-4 Continued
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Figure 3-5: Overexpression of PKCι/λ attenuated the insulin signaling cascade in
ZL primary rat hepatocytes. ZL rats were fed standard chow for eight weeks before
primary hepatocytes were harvested. Purified Ad-Prkci was added in the medium A
during the pretreatment period to allow the overexpression of PKCι/λ. Purified Ad-β-gal
was used as a control recombinant adenovirus. The primary hepatocytes were then
incubated in fresh medium A with increasing concentrations of insulin (0 nM to 100 nM)
for 15 min before whole cell lysate preparation. The whole cell lysates were subjected to
immunoblot analysis with antibodies indicated in the figure. The figure shows the
representative result of three parallel experiments obtained from three sets of animals.
(A) Immunoblot analysis of Ad-Prkci infected ZL primary hepatocytes treated with
increasing concentrations of insulin for 15 min. (B) Densitometry analyses of the
immunoblot results. Data are arbitrary intensity units expressed as mean ± SEM. All
p<0.05; a<b, a’<b’, c<d, e<f using one way ANOVA. * for comparing the difference
between ZL and ZF using two way ANOVA.
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levels of IRS1. However, there was no significant difference between Ad-β-gal and AdPrkcz infected hepatocytes regarding FAS, ACC or phospho-ACC Ser79.
Overexpression of PKCι/λ did not significantly change the levels of PKCζ or ACC
(Figure 3-5). However, there was a slight but significant elevation in the levels of FAS
and phospho-ACC Ser79. Ad-Prkci infected hepatocytes showed similar level of total
AKT to that of Ad-β-gal infected primary hepatocytes. But interestingly, the levels of
IRS1, phospho-AKT Thr450, and insulin-induced phospho-AKT Ser473 and Thr308
were significantly decreased in primary rat hepatocytes overexpressing PKCι/λ.
These data collectively demonstrate that overexpression of aPKCs attenuates the
insulin signaling cascade in ZL primary rat hepatocytes.
3.5 Overexpression of PKCζ and PKCι/λ impaired the insulin-regulated gene
expression in ZL primary rat hepatocytes.
To investigate whether aPKCs affect hepatic insulin-regulated gene expression, we
examined the transcript levels of Gck, Pck1, Srebp-1c and liver type pyruvate kinase gene
(Pklr) in response to increasing concentrations of insulin treatments in ZL primary rat
hepatocytes overexpressing PKCζ or PKCι/λ. Figure 3-6A showed that in hepatocytes
overexpressing β-GAL, insulin dose-dependently induced the Gck expression.
Overexpression of either PKCζ or PKCι/λ in ZL primary hepatocytes elevated the basal
transcript level of Gck. Additionally, the fold inductions of Gck expression in response to
0.1-100 nM insulin treatments were abolished in hepatocytes overexpressing PKCζ or
PKCι/λ.
Insulin at 0.1-100 nM dose-dependently suppressed the Pck1 expression in
hepatocytes overexpressing β-GAL by 80% (Figure 3-6B). At 0 nM insulin treatment, the
transcript levels of Pck1 in hepatocytes overexpressing PKCζ or PKCι/λ were about 3
times of that in hepatocytes overexpressing β-GAL. Moreover, the insulin-suppressed
Pck1 expression was abolished in hepatocytes overexpressing PKCζ or PKCι/λ.
Figure 3-6C showed that insulin dose-dependently induced the Srebp-1c expression in
hepatocytes overexpressing β-GAL. Overexpression of either PKCζ or PKCι/λ in ZL
primary hepatocytes elevated the basal transcript level of Srebp-1c. In addition, the
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Figure 3-6: Overexpression of PKCζ and PKCι/λ impaired the insulin-regulated
gene expression in ZL primary rat hepatocytes. ZL rats were fed standard chow for
eight weeks before primary hepatocytes were harvested. Purified Ad-Prkcz and Ad-Prkci
were added in the medium A during the pretreatment period to allow the overexpression
of PKCζ and PKCι/λ. Purified Ad-β-gal was used as a control recombinant adenovirus.
The primary hepatocytes were then incubated in fresh medium A with increasing
concentrations of insulin (0 nM to 100 nM) for 6 hrs before total RNA extraction. Total
mRNA was extracted, synthesized into cDNA, and then subjected to real time PCR
analysis for the expression levels of Gck (A), Pck1 (B), Srebp-1c (C), and Pklr (D). The
data were expressed as fold induction. The gene transcript levels from Ad-β-gal infected
primary hepatocytes with 0nM insulin treatment were arbitrarily set to 1. All p<0.05; for
(A), a>b; for (B), c>d; for (C), e<f using one-way ANOVA; * for comparing fold
inductions at corresponding treatments using one-way ANOVA.
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insulin-induced Srebp-1c expression was abolished in hepatocytes overexpressing PKCζ
or PKCι/λ.
The mRNA levels of Pklr in ZL primary hepatocytes overexpressing β-GAL, PKCζ
or PKCι/λ were not affected by insulin (Figure 3-6D). However, the expressions levels of
Pklr were significantly higher at 0-1 nM insulin in hepatocytes overexpressing PKCζ or
PKCι/λ than in hepatocytes overexpressing β-GAL.

4. Discussion
Here, we have shown that the expression levels of PKCζ, but not that of PKCι/λ, are
higher in the livers of ZF rats than ZL rats. Since the insulin-regulated gene expression is
impaired in primary hepatocytes from ZF, but not ZL rats fed ad libitum, we
hypothesized that alteration of the aPKC expression in hepatocytes may play a role in the
impairment. Therefore, PKCζ and PKCι/λ were successfully overexpressed using
recombinant adenoviruses in ZL primary hepatocytes. It seems that the overexpression of
either PKCζ or PKCι/λ is sufficient to alter basal and insulin-regulated gene expression in
hepatocytes from ZL rats. We have tried and failed to detect the activities of the aPKC in
both liver and primary hepatocyte samples, including those samples from hepatocytes
with overexpression of PKCζ and PKCι/λ. The lack of antibody for immune-precipitation
or a specific substrate peptide can be the reason. Further experiments are warranted when
additional means become available for determination of their activities.
In this study, we demonstrate that adenoviral-mediated overexpression of PKCζ and
PKCι/λ leads to the impairment of insulin-regulated Gck, Srebp-1c, and Pck1 expressions
in the ZL primary rat hepatocytes (Figure 3-6). At mRNA level, the observed impairment
has two main characteristics: (1) the overexpression of either PKCζ or PKCι/λ causes the
elevation of basal mRNA levels of Gck, Srebp-1c, Pck1, and Pklr; (2) the overexpression
abrogates the insulin action to induce Gck and Srebp-1c expressions, and suppress Pck1
expression in the primary hepatocytes.
The impairment of the insulin-regulated gene expression might be attributed to the
reduced activation of AKT/PKB in cells with overexpression of PKCζ or PKCι/λ. In ZL
hepatocytes infected with ad-β-GAL, insulin dose-dependently induces the activation of
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AKT/PKB and protein levels of IRS1. On the other hand, PKCζ or PKCι/λ
overexpression attenuates the insulin-induced phosphorylation of AKT, and decreases the
protein level of IRS1 in the hepatocytes, which suggests a diminished IRS/PI3K/AKT
signaling cascade (Figure 3-4 and 3-5). However, the expression levels of AKT/PKB and
its activation status seem to be not different between the Ad-β-gal control groups and
overexpression groups. It indicates that other mechanisms may contribute to the elevation
of the basal expression of the same genes in hepatocytes with overexpression of PKCζ or
PKCι/λ. Collectively, these data show that PKCζ and PKCι/λ are critical regulators of
hepatic glucose and lipid metabolism.
GCK catalyzes the phosphorylation of glucose into glucose-6-phosphate in the ratelimiting step of glycolysis in the liver [310]. The hepatic regulation of the Gck expression
depends on the insulin-mediated activation of IRS/PI3K/AKT pathway [324,328,329]. It
has been shown that the Gck expression requires mammalian target of rapamycin
complex 2 (mTORC2) induced phosphorylation of AKT at Ser473 [18]. In Figure 3-4
and 3-5, PKCζ or PKCι/λ overexpression diminished phosphorylation of AKT at Ser473
with decrease of the IRS1 protein expression. This is accord with previous reports that
aPKCs act as negative feedback regulators of insulin signaling pathway by promoting
serine phosphorylation and tyrosine de-phosphorylation of IRS proteins [330-332]. Thus,
the possible reduction of the activation of IRS/PI3K/AKT pathway due to PKCζ or
PKCι/λ overexpression may impair the insulin-regulated Gck expression. Additionally,
insulin-induced Gck expression is mediated through a selection of transcription factors,
including hepatocyte nuclear factor 4 (HNF4), forkhead box protein O1 (FOXO1),
SREBP-1c, liver x receptor α (LXRα), and peroxisome proliferator-activated receptor γ
(PPARγ) [24,333-335]. Since the knowledge about the non-kinase activities and
endogenous substrates of PKCζ or PKCι/λ is limited, it is also possible that PKCζ or
PKCι/λ directly regulate Gck expression through certain transcription factors, which
increases its basal transcript level.
PEPCK catalyzes the rate limiting enzymatic reaction in gluconeogenesis, by which
oxaloacetate is converted into phosphoenolpyruvate [336]. In the liver, the insulinsuppressed Pck1 expression is purportedly mediated through three pathways: (1) the
phosphorylation and inactivation of FOXO1 via IRS/PI3K/AKT [337,338]; (2)
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antagonizing the glucagon-induced PPARγ co-activator 1 (PGC1α) expression [339]; (3)
the phosphorylation of CREB binding protein (CBP) via IRS/PI3K/aPKCs [340,341].
Interestingly, despite the high levels of aPKCs to suppress Pck1 expression via CBP, the
diminished IRS/PI3K/AKT pathway plays a dominant role in the primary hepatocytes
overexpressing aPKCs. It not only leads to an increase in the basal transcript of Pck1
mRNA, but also abrogates the insulin-mediated Pck1 suppression (Figure 3-6B).
Incidentally, the activities of aPKC isoforms are elevated in the livers of type 2 diabetic
individuals [31,35,36]. Treatment of hepatocytes from these individuals with aPKC
inhibitors decreases the basal transcript levels of gluconeogenic genes [35,36]. These data
suggest that aPKCs are prominent positive regulators of hepatic gluconeogenesis.
SREBP-1c is a master transcriptional factor for the expression of lipogenic genes in
the liver [342]. The insulin-induced Srebp-1c expression requires the activation of
PI3K/AKT, and the mTORC2-mediated phosphorylation of AKT at Ser473 [18,324].
With the help of pharmacological inhibitors, the activation of mTORC1 downstream of
AKT is identified as an indispensible step in the induction of Srebp-1c [316]. On the
other hand, the activation of PI3K subsequently activates aPKC in the liver, which
promotes Srebp-1c expression and lipogenesis [30-34]. Despite the diminished
IRS/PI3K/AKT signaling pathway and the abolished insulin-regulated Srebp-1c
expression, PKCζ or PKCι/λ overexpression increases the basal transcript level of Srebp1c in the hepatocytes (Figure 3-6C). Interestingly, PKCζ or PKCι/λ overexpression only
slightly induced the protein levels of FAS and ACC (Figure 3-4 and 3-5). One possibility
is that the induced transcripts might not have been translated in the presence of
overexpression of PKCζ or PKCι/λ. Alternatively, diminished IRS/PI3K/AKT signaling
pathway results in decreased activation of p70 S6-kinase (S6K), which is required for the
SREBP-1c processing to generate nuclear SREBP-1c [343]. In this regard, the protein
levels of FAS and ACC do not significantly increase due to unstimulated SREBP-1c
processing. Moreover, there might be a lag time for us to see the elevation of mRNA to
the protein, the down-stream targeted mRNA and proteins. Nevertheless, the protein
levels of ACC and FAS are maintained at a high level in the hepatocytes and livers from
ZF rats, demonstrating the metabolic defects associated with these insulin-resistant
animals. Further investigations are needed to delineate the sequential events associated
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with the elevation of the hepatic lipogenesis upon insulin stimulation and activation of
AKT and aPKC isoforms.
It is interesting to note that the Prkcz mRNA and PKCζ protein, but not that of Prkci
mRNA and PKCι/λ protein levels are elevated in the liver of ZF rats. Insulin at 1 nM and
up significantly induces the expression levels of Prkci mRNA, a process that is blunted in
the presence of PKCζ overexpression. On the other hand, insulin does not affect the
expression of Prkcz mRNA. Additionally, PKCι/λ overexpression alone does not affect
Prkcz mRNA expression. However, PKCι/λ overexpression introduced the insulinmediated suppression of Prkcz mRNA expression. These data indicate that there are
crosstalk between PKCζ and PKCι/λ pathways, which may mutually regulate the
expression of each other at mRNA levels in response to hormonal or nutritional stimuli.
The alteration of this mutual regulation mechanism probably is associated with the
development of the impairment of insulin signaling. Further studies are warranted.
In summary, we have shown that aPKC overexpression in ZL primary hepatocytes
impairs the insulin-regulated gene expression, and attenuates the IRS/PI3K/AKT part of
the insulin signaling pathway. It demonstrates that the alteration of the expression levels
of aPKC leads to reduction of the phosphorylation of AKT and its downstream pathways.
These results demonstrate the critical roles of aPKCs in the regulation of hepatic glucose
and lipid metabolism at gene expression level, and provide interesting insights into the
development of the hepatic insulin resistance and type 2 diabetes.
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CHAPTER IV. UNPUBLISHED DATA, CONCLUSION AND
FUTURE DIRECTIONS
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1. Unpublished data
1.1 The effect of retinoids on the glucose-stimulated insulin secretion from INS-1
cells.
1.1.1

Background summary

Islets of Langerhans, which account for less than 2% of the total pancreas mass,
produce and secret anabolic hormone insulin from β-cells. The secretion of insulin is
mainly stimulated by the influx of glucose into β-cells. It has been also shown that amino
acid and neural stimuli can stimulate insulin secretion [274].
Glucose-stimulated insulin secretion (GSIS) from the pancreatic β-cells is a well
characterized physiological event [344]. Upon entry into the pancreatic β cells, glucose
will be broken down via the typical glycolysis and citric acid cycle, which results in the
production of ATP. An elevated ATP:ADP ratio in the cytosol will inhibit the ATPsensitive potassium ion channel in the cell membrane, which in turn facilitates the
opening of the calcium ion channel. An influx of Ca2+ into the cell triggers the release of
insulin [344].
Previous studies showed that VAD rats had impaired GSIS from isolated islets, but
the insulin content and morphology of the islet cells were unchanged [278]. In
comparison, VA deficiency reduces the β-cell mass in fetal islets by reducing the fetal βcell replication [277]. On the other hand, the effects of VA and its metabolites on isolated
islets and insulin secreting cells are both chemical- and dosage-dependent (See Chapter 1,
section 9.4). In insulin-secreting RINm5F cells, both all-trans-RA and 9-cis-RA were
found to increase insulin secretion. However, all-trans-RA could also inhibit cell growth
and increase apoptosis [280]. Several proteins including nuclear receptors LXR, RARs
and RXRs, and transglutaminase were hypothesized to mediate the effects of retinoids on
the GSIS, However, the specific molecular mechanisms involved in the process are still
unknown [281]. INS-1 cells are well established cell lines for the elucidation of GSIS
mechanisms [345]. Here, standard GSIS assay was performed on INS-1 parental cells,
832/13, 833/15 and 833/117 cell lines to investigate the effects of retinal, retinal and RA
on the GSIS.
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1.1.2

All-trans-RA has divergent effects on the GSIS of different INS-1 cell lines

INS-1 parental cells, 832/13, and 833/117 cells were seeded in 12 well tissue culture
plate and cultured in standard RPMI 1640 medium (supplemented with 10 mM glucose, 2
mM

glutamine,

1

mM

sodium

pyruvate,

10%FBS,

10

mM

HEPES,

1%

penicillin/streptomycin, and 50 µM β-mercaptoethanol) at 37˚C and 5% CO2 for 3 days to
reach 70% confluency. The INS-1 cells were then treated with 5µM all-trans-RA in the
same fresh RPMI 1649 medium at 37˚C and 5% overnight. After the removal of the
medium, the cells were treated in secretion assay buffer (SAB, 114 mM NaCl, 4.7 mM
KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 2.5 mM CaCl2, 25 mM NaHCO3, 20 mM
HEPES, 1% BSA, pH 7.4) with either 3 mM or 15 mM glucose to measure insulin
secretion. After incubation at 37˚C for 2 hrs, the supernatant SAB and the cells were
collected into separate centrifuge tubes (Figure 4-1). The insulin content in the SAB was
measured using the Siemens Insulin Coat-A-Count® Kit (06615423). The collected cells
were lysed by 0.5% (v/v) Triton X-100. The total protein was measured using Pierce™
BCA Protein Assay Kit.
833/15 cells were used to examine the effects and difference between the
pretreatment and the acute treatment of all-trans-RA on GSIS (Figure 4-1). The cells are
cultured in RPMI 1640 medium containing 3 mM glucose. The experiment procedure is
similar to the one described above, except that: (1) in the pretreatment condition, the cell
are treated with 5µM all-trans-RA in the medium at 37˚C and 5% CO2 overnight; (2) in
the acute treatment condition, 5µM all-trans-RA is added to the SAB containing either 3
mM or 15 mM glucose, and incubated at 37˚C for 2 hrs.
The results (Figure 4-1) showed that 5µM all-trans-RA significantly enhanced the
GSIS of 832/13 and 833/117 cells by 15 mM glucose, but not by 3 mM glucose. It
suggests that all-trans-RA may potentiate the GSIS of INS-1 cells at the stimulatory
concentrations of glucose. As expected, INS-1 parental cells did not show any response
to either glucose stimulation or all-trans-RA treatment. One possible explanation is that
the INS-1 parental cells a mixture of insulinoma cells. It is reported that most of the INS1 parental cells have lost the GSIS [346].
All-trans-RA pretreatment of 833/15 cells caused a significant increase of insulin
secretion by 3 mM glucose, but not by 15 mM glucose. Interestingly, this phenomenon
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Figure 4-1: The effects of all-trans RA on the GSIS of INS-1 cells. INS-1 cells were
cultured in standard RPMI 1640 medium at 37˚C for 3 days to reach 70% confluence.
The cells were treated with 5 µM all-trans RA, and the insulin secretion assay was
performed as indicated by the schematic graphs. The secreted insulin during 2 hrs is
measured and the data were normalized to the protein content of the cells. The data are
presented as mean ± SD. (A), the effect of all-trans RA on the GSIS of INS-1 parental,
832/13 and 832/117 cells. (B) The pretreatment and acute treatments of all-trans RA on
the GSIS of 833/15 cells.
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was not apparent in the acute treatment condition. These results collectively suggest that
all-trans-RA has divergent effects on the GSIS of INS-1 cell lines.
1.1.3

The effects of retinoids on the GSIS from isolated subclones of INS-1
parental cells.

INS-1 cell lines 832/13, 833/15 and 833/117 contain exogenous human insulin gene
[346,347]. To establish an INS-1 cell line without human insulin gene, INS-1 parental
cells were trypsinized and subjected to serial dilutions with RPMI 1640 medium in a 96well plate. After incubation at 37˚C and 5% CO2, the INS-1 cells originated from a single
cell from the dilution of the parental cells and maintained stable growth in culture were
picked for further analyses. In particular, two isolated subclones, INS-1 6D and 8E
manifested stable propagation properties and were used to investigate the effects of alltrans-retinol, retinal and RA on the GSIS (Figure 4-2). Standard insulin secretion assay
showed that INS-1 8E manifested high basal insulin secretion when it was cultured in
RPMI 1640 containing 10 mM glucose (Figure 4-2). INS-1 6D showed low basal insulin
secretion, but high GSIS by 15 mM glucose (Figure 4-2). These data further confirmed
that INS-1 parental cells are a mixture of subclones, which have diverse GSIS capacities.
The effects of retinoids on the GSIS were performed on INS-1 6D and INS-1 8E
according to the procedures described above with RMPI 1640 medium containing 10 mM
glucose. The results showed that 5µM all-trans-retinol and 5µM all-trans-retinal did not
affect the GSIS of INS-1 6D cells. 5µM all-trans-RA, however, suppressed the GSIS of
INS-1 6D cells (Figure 4-2). In addition, 5µM all-trans-retinol and 5µM all-trans-retinal
and 5µM all-trans-RA did not affect the GSIS of INS-1 8E cells (Figure 4-2).
Interestingly, when INS-1 8E cells were cultured in RPMI1640 medium with 3 mM
glucose, the cells regained the stimulatory response of insulin secretion pattern by 15 mM
glucose (Figure 4-2). Furthermore, all-trans-RA significantly decreased GSIS by 15 mM
glucose in INS-1 8E. In contrast, all-trans-RA only significantly decreased the GSIS by
15 mM glucose in INS-1 6D, when the cells were incubated in RMPI 1640 medium with
all-trans-RA (Figure 4-2). These results showed that all-trans-RA had suppressive effect
on the GSIS of INS-1 cells, which do not contain exogenous human insulin gene.

!

118

Figure 4-2: The effects of all-trans retinol, retinal and RA on the GSIS of INS-1 6D
and 8E cell lines. INS-1 6D and 8E cells lines were obtained from isolation of single
clones from parental cells. Insulin secretion assays were performed as indicated in the
text. (A) Insulin secretion of INS-1 6D and 8E in response to 3 mM and 15 mM glucose
stimulation. (B and C) The effects of all-trans retinol, retinal and RA on the GSIS by 3
mM and 15 mM glucose in INS-1 6D and 8E cells. (D) The differential all-trans RA
treatments on the GSIS by 3 mM and 15 mM glucose in INS-1 6D and 8E cells.
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1.2 Chromatin immunoprecipitation analyses of the Gck gene promoter in primary
hepatocytes
1.2.1

Background summary

Glucokinase (GCK, gene Gck), also known as hexokinase D, is a key enzyme in
glucose metabolism. It catalyzes the irreversible conversion of glucose into glucose-6phosphate [310]. Other hexoses such as fructose and mannose can also be phosphorylated
by this enzyme, but to a lesser content [310]. Given its important role, Gck was proposed
to be a gene involved in the pathogenesis of type 2 diabetes. Genetic studies have
revealed several diseases, such as maturity onset of diabetes of the young (MODY) [348],
persistent hyperinsulinemic hypoglycemia in infancy (PHHI) [349], that are associated
with mutated GCK gene. The altered glucokinase activity directly leads to abnormal
metabolic profile in these patients, demonstrating the central role of glucokinase in
regulating glucose metabolism.
Even though glucokinase is expressed in multiple organs, including liver, pancreas,
brain, intestine and gonads, its physiological role of maintaining glucose homeostasis is
mainly carried out in the hepatocytes and pancreatic β-cells [310]. Studies in the 1960s
and 1980s established that glucokinase in the former cell type helped remove glucose
from the blood stream, whereas in the latter cell type it worked as a glucose sensor [350352]. The differential functions of glucokinase in hepatocytes and pancreatic β-cells were
mediated by different stimuli, with the former responding to insulin, and the latter to
glucose [353]. Additionally, the transcription of glucokinase gene is regulated by tissuespecific enhancers, thereby providing molecular evidence to its differential functions
[354-357]. In the hepatocytes, previous luciferase activity assay showed that an upstream
region up to -1000bp relative to the transcription start site of Gck was able to retain
maximal transcription ability of the intact promoter [357]. In order to investigate the
transcriptional machinery at the promoter of Gck upon insulin and RA treatment,
chromatin immunoprecipitation (ChIP) assay was performed.
1.2.2

Procedures of the ChIP assay.

Primary hepatocytes were isolated from ZL rats fed chow diet for 8 weeks according
to the previously described protocol [235]. The cells were plated at the concentration of
1x107 cells per 150mm cell culture dish, and pretreated with 100 nM triiodiothyronine
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(T3), 100 nM dexamethasone and 1 nM insulin in M199 at 37˚C and 5% CO2 overnight.
After pretreatment, the primary hepatocytes were treated 2 nM insulin and 5µM RA for
increasing time period (0, 0.5, 1, 2hr), and then cross-linked by formaldehyde (1% final
concentration) for 10 min at room temperature. The cells were dounced by a Whitmann
type B dounce to release nuclei. The nuclei were then sonicated with Branson M150
sonicator to generate DNA fragments of 100-1000bp. The fragmented chromatin was
incubated with specific antibodies, including anti-Acetyl-histone H3 (Anti-AcH3, Cell
Signaling, Danvers, MA, USA) and anti-Rpb1 (Cell Signaling). Normal Rabbit IgG
(Millipore, Billerica, MA, USA and Cell Signaling) was used as non-specific control.
Target chromatins were pulled down by Protein A or G beads, eluted, and subjected to
de-crosslinking. The released DNA fragments were purified and tested by standard PCR
with designed primer pairs. The amplicons were stained with ethidium bromide and
visualized in 2% agarose gel with Kodak imaging system.
Semi-quantitative analysis was performed with ImageJ software (National Institute
Health, MD), which measures the intensity of color of a given area in a picture. Black
gives zero intensity by default. Gel images were thus loaded onto the software. A preset
area was selected to cover a single DNA band on the gel. Then the brightness of the DNA
band was measured and transformed into numbers by the software. The relative amount
of the DNA, which corresponds to the brightness of the band, was expressed as the
percentage compared to the amount of INPUT DNA.
1.2.3

Optimization of sonication condition

3 × 107 primary hepatocytes were suspended in 3 ml nuclei lysis buffer. (50 mM TrisHCl, 10 mM EDTA, 1% SDS). Cells were sonicated using 35% power output with a 10
seconds ON/ 40 seconds OFF cycle. Total sonication time is showed in Figure 4-3. 100µl
cell lysis was taken out at each time point. 10µl 5M NaCl were added to each sample,
which was subjected to de-crosslinking at 65˚C overnight. Total DNA was then extracted
with the phenol/chloroform extraction method. 5µg of DNA from each sample was
loaded on a 2% agarose gel. As it shows in Figure 4-3, a total sonication time of 6 min
was sufficient to break down DNA into 200bp fragments.
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Figure 4-3: The optimization of sonication condition.

Figure 4-4: Comparison of whole cell and cell nuclei in the ChIP assay. “+”
represents the positive control for PCR.
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1.2.4

Test whether whole cells or nuclei should be used in the ChIP assay so that
less background signal is obtained

Whole cell samples were acquired from two individual rats. Cell nuclei samples were
acquired from two individual rats. All samples were sonicated at 35% power with 10
seconds ON/50 seconds OFF cycle for a total of 6 min. Chromatin was precleared with
20µl Santa Cruz protein A/G agarose beads for 2 hrs at 4˚C. Precleared chromatin was
aliquoted 100µg DNA per IP. The IP was performed by adding 2µg rabbit IgG overnight
and 10µl Millipore Protein A Magnetic Beads (MI) or 10µl Cell Signaling Protein G
Agarose Beads (CS) for 2 hrs. The final elute was amplified with primer pairs
oGC786/797 which target the Gck promoter. Figure 4-4 showed that using cell nuclei
gave out less background signal. The graph also suggested that MI and CS beads gave out
similar background signal.
1.2.5

Test the amount of chromatin needed for each IP

Decreasing amount of precleared chromatin (100µg, 50µg, 25µg, 10µg) was used for
each IP. DynaBeads (Invitrogen) was either preblocked with 1 mg/ml BSA and 30 µg/ml
pGL-Basic plasmid at 4˚C for 2 hrs. IP was done by adding 2µg rabbit IgG or 2µl antiAcH3. ChIP assay was performed as described in the protocol. The final elute was
amplified with primer pairs oGC788/794 which target Gck promoter. The result (Figure
4-5) showed that decreasing initial amount of chromatin for each IP would decrease the
signal, thus decrease the resolution of the assay.
1.2.6

Test of preclearing condition

For each IP, 100 µg crude chromation is used. To test preclearing condition, two
different chromatin samples were precleared by 20 µl Santa Cruz protein A/G beads with
or without 2 µg Rabbit IgG overnight. Then IP was performed by using 2 µg Rabbit IgG.
The final elute was amplified with primer pairs Cyp26a1-1/2. The result (Figure 4-6)
showed that adding IgG at the preclearing step did not improve background signal.
1.2.7

Test of different beads and preblocking condition

100µg precleared chromatin was used for each IP. Millipore Magnetic Beads was either
preblocked with 1 mg/ml BSA and 30 µg/ml pGL-Basic plasmid, or not blocked at 4˚C
for 2 hrs. IP was done by adding no reagent or 2µg rabbit IgG or 2µl rat serum. ChIP
assay was performed as described in the protocol. The final elute was amplified with
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Figure 4-5: Test of the amount of chromatin needed for each IP.

Figure 4-6: Test of the preclearing condition.
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primer pairs oGC788/794 which target Gck promoter. Similar experiments were also
performed for the Cell Signaling Protein G Beads and the Invitrogen DynaBeads. As we
can see from Figure 4-7, the preblocking did not significantly reduce background signal.
1.2.8

Test beads amount and antibody amount

100µg precleared chromatin was used for each IP. DynaBeads was preblocked with 1
mg/ml BSA and 30 µg/ml pGL-Basic plasmid at 4˚C for 2 hrs. IP was done by adding
decreasing amount of rabbit IgG or anti-AcH3 as shown in the Figure 4-8. ChIP assay
was performed as described in the protocol. The final elute was amplified with primer
pairs oGC788/794 which target Gck promoter. As we can see, the combination of fewer
beads and antibody would lead to loss of signal.
1.2.9

Glycine interferes with the specific antibody-antigen binding

For each IP, 100µg precleared chromatin was used. In the IP system increasing
amount of glycine (0 nM to 10 mM) was added. IP was performed by using 2µg rabbit
IgG or 2µg anti-AcH3 antibodies overnight. The rest of the ChIP was performed
according standard protocol. As Figure 4-9 suggests, glycine interferes with Ag-Ab
binding at 0.1 mM and above without affecting non-specific binding.
1.2.10 No change of RNA polymerase II binding was observed at the hepatic Gck
promoter 2 hrs after RA and Insulin treatment.
Primary hepatocytes were plated at the concentration of 1x107 cells per 150mm cell
culture dishes, and pretreated with 100 nM triiodiothyronine (T3), 100 nM
dexamethasone and 1 nM insulin in M199 overnight. After pretreatment, the primary
hepatocytes were exposed to 2 nM insulin and 5µM RA for increasing time period (0, 0.5,
1, 2hr), and then cross-linked by formaldehyde (1% final concentration) for 10min at
room temperature. The nuclei of the cells were released by douncing with a type B
douncer, and then sonicated at the 35% power output with 10sec ON/ 50sec OFF cycle
for a total of 6min. The fragmented chromatin was incubated with 2µg Anti-AcH3, and
2µg anti-Rpb1. Normal rabbit IgG was used as non-specific control. Target chromatins
were pulled down by 10µl Invitrogen Dynabeads, eluted, and subjected to de-crosslinking.
The released DNA fragments were purified and tested by standard PCR with primer pair
oGC788/794, which target the promoter region of hepatic Gck. The amplicons were
stained with ethidium bromide and visualized in 2% agarose gel. The result (n=3) showed
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Figure 4-7: Test of different beads and the preblocking condition.
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Fig. 4-8: Test of beads amount and antibody amount.

Figure 4-9: Glycine interferes with the specific antibody-antigen binding.
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that within 2 hrs of treatment with 2 nM insulin and 5µM RA, the binding of RNA
polymerase II to the promoter of hepatic Gck did not significantly change (Figure 4-10,
Two-way ANOVA, p>0.05 for the time variable).

2. Conclusion and future directions
2.1 Conclusion
This dissertation explores the effects of hormonal and dietary factors on glucose and
lipid metabolism in the liver. Specifically using ZF rats, a genetic model of obesity and
insulin resistance, current research in the dissertation probes the molecular mechanisms
underlying two study questions: (1) How does VA affect the hepatic glucose and lipid
metabolism at the gene transcription level? (2) How does aPKC contribute to the hepatic
insulin resistance in the liver of ZF rats? The answers to these two questions are
delineated in the Chapters II and III, which provide insights into the development of
hepatic insulin resistance and metabolic disease.
In Chapter II, we investigated the effects of food intake and VA status on the insulinregulated gene expression in primary hepatocytes from ZL and ZF rats, and obtained the
following results. First, the insulin-regulated Gck, Pck1 and Srebp-1c expressions were
impaired in the primary hepatocytes of the ZF rat fed chow diet ad libitum, confirming
our previous observation [312]. The impairment was partially corrected if the ZF rats
were fed a VAD diet ad libitum to induce VA deficiency, or they were pair-fed the same
amount of a VAS diet in calories consumed by their VAD counterparts. Second, the ZL
and ZF rats pair-fed the isocaloric VAS diet had higher body mass than those fed the
VAD diet at the end of dietary manipulation. The pair-fed ZL and ZF rats tended to
overeat when sufficient amount of food was provided at the end of the 8-week feeding
paradigm. Third, transient over intake of the VAS diet for one day caused the impairment
of insulin-regulated Gck, Pck1 and Srebp-1c genes expression in the primary hepatocytes
of both pair-fed ZL and ZF rats. Fourth, transient overeating for one day greatly affected
the expression levels of genes involved in VA metabolism in response to insulin
treatment in the hepatocytes of ZL and ZF rats. Taken together, these observations show
that both food intake and VA status of rats affect hepatic insulin sensitivity at gene
expression level in the hepatocytes.
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Figure 4-10: Representative ChIP assay results and the densitometry analysis of
three independent experiments. The error bar represents S.E.M.
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In Chapter III, we investigated the roles of PKCζ and PKCι/λ on the insulin-regulated
gene expression in the liver tissues and primary hepatocytes of Zucker rats, which yielded
the following findings. First, ZL and ZF rats exhibited similar mRNA and protein levels
of PKCι/λ in the liver tissues and primary hepatocytes. The mRNA and protein levels of
PKCζ, and the level of phosphorylated PKCζ/λ, on the other hand, were elevated in the
liver tissues and primary hepatocytes of ZF rats. Second, the phosphorylation levels of
AKT Ser473 were elevated in the liver tissues of ZF rats. However, this induction does
not seem to affect the impairment of insulin-regulated gene expression in ZF hepatocytes.
The basal level of AKT Ser473 phosphorylation in ZF primary hepatocytes dropped upon
pretreatment, which was not associated with any return of insulin-regulated gene
expression in the same cells, suggesting other factors probably play a role in the
impairment. This conclusion is supported by the fact that the levels of lipogenic enzymes
were still elevated in the primary hepatocytes of ZF rats after pretreatment. Third,
adenoviral mediated PKCζ and PKCι/λ overexpression blunted the insulin-induced
phosphorylation of AKT, and decreased the IRS1 level in the primary hepatocytes of ZL
rats. Fourth, adenoviral mediated PKCζ and PKCι/λ overexpressions in the ZL primary
hepatocytes attenuated the insulin-regulated Gck, Pck1 and Srebp-1c genes expression.
These findings collectively demonstrate that PKCζ and PKCι/λ serve as negative
feedback regulators of hepatic insulin signaling cascade, and play critical roles in the
regulation of hepatic glucose and lipid metabolism.
2.2 Future directions
Even though the results presented in this dissertation have provided ample evidence
that both VA and aPKC affect insulin-regulated gene expression in the liver, future
research questions can be extracted from the findings to help extend our understandings
of the development of insulin resistance and its related metabolic diseases.
2.2.1

How does overeating for one day affect the metabolic profile of Zucker rats?

In this dissertation, we found that overeating of a VAS diet for one day altered the
VA metabolic gene expression, and caused the impairment of insulin-regulated gene
expression in the primary hepatocytes of ZL and ZF rats. It would be interesting to see if
these gene expression changes lead to broader metabolic changes in vivo. For example,
will the transient overeating lead to alterations of serum levels of insulin, glucagon and
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leptin? Does dysregulated hepatic Gck, Pck1 and Srebp-1c genes expression forebode
increased serum glucose level, hepatic glucose production and hepatic lipogenesis?
Answers to these questions will provide additional information about the development of
insulin resistance by overnutrition.
2.2.2

How does RA regulate the hepatic expression of Gck, Pck1 and Srebp-1c?

It is evident that RA, as a natural metabolite of VA, regulates the hepatic expression
of Gck, Pck1 and Srebp-1c. However, the knowledge about the transcriptional machinery
that mediates the actions of RA in the expression of Gck, Pck1 and Srebp-1c is still
limited. More detail studies are needed to identify the transcription factors that are
responsible for mediating both RA and insulin effects. By using biochemical and
molecular research tools, such as ChIP and mobility shift assay, we should be able to
delineate the components of transcriptional machinery in the promoters of those genes.
The findings will help identify therapeutic targets to combat dysregulated metabolic gene
expression in obesity and type 2 diabetes.
2.2.3

How is the gene expression of Prkcz and Prkci regulated?

One interesting finding in Chapter III was that insulin seemed to attenuate the
expression of Prkci in the primary hepatocytes overexpressing Prkcz. This suggests that
Prkci expression is regulated by both insulin and PKCζ. Given the fact that: (1) PKCζ
and PKCι/λ share high homology; (2) PKCζ and PKCι/λ both attenuate the insulin
signaling cascade in the hepatocytes when overexpressed, the investigation into how their
gene expression is regulated will further delineate the roles of aPKC in the development
of insulin resistance.
2.2.4

What are other downstream substrates of PKCζ and PKCι/λ in the
regulation of hepatic gene expression?

In Chapter III, we demonstrated that PKCζ and PKCι/λ overexpressions increased the
basal transcript levels of Gck, Pck1 and Srebp-1c. It is possible that these increases are
mediated through the modification of certain transcription factors or downstream proteins
targeted by PKCζ and PKCι/λ. The discovery of these downstream substrates will
provide new research ground for the understanding of hepatic insulin resistance and its
related metabolic diseases.
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Table 1-5: List of real time PCR primers used in the dissertation.
Gene
Gck
Pck1
Srebp-1c
Pklr
Rdh2
Raldh1
Raldh4
Cyp26a1
Rbpr2

Real-time PCR primers
5′-CGAGATGCTATCAAGAGGAGAG-3′
5′-TCACATTGGCGGTCTTCATAG-3′
5′-AGTCACCATCACTTCCTGGAAGA-3′
5′-GGTGCAGAATCGCGAGTTG-3′
5′-GGAGCCATGGATTGCACATT-3′
5′-AGGCCAGGGAAGTCACTGTCT-3′
5′-CGTTTGTGCCACACAGATGCT-3′
5′-CATTGGCCACATCGCTTGTCT-3′
5′-CAAGTTCTTCTACCTCCCCATGA-3′
5′-TCCAGTAGAAAAGGGCATCCA-3′
5′-ATGGTCTAGCAGCAGGAGT-3′
5′-CCAGACATCTTGAATCCACCGAA-3′
5′-TGACCCAAGAAATAGCCAAAGAA-3′
5′-CTAGGCAACTGCCAGCACTTTT-3′
5′-AGTGATGGGCGCGGATAAT-3′
5′-TGCACTGACACCAACCGGT-3′
5′-GTCAGCTCCATCTTGGGCTT-3′
5′-ACCTCCCTAGAAACTGCCCA-3′

Table 1-6: List of ChIP PCR primers used in the dissertation.
No.
oGC786
oGC797
oGC788
oGC794

!

ChIP PCR primers
5′-GGCCAAACCCAAAGAAAGGAT-3′
5′-CTGCGGAGGGGTTGACGAT-3′
5′-CCCACGAGGATCCCCCACTA -3′
5′-GGTTTGACAAAGGCCACAG -3′
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